var title_f9_1_9232="TR four chamber color Doppler echo 1";
var content_f9_1_9232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68814/4chcotr1_conv.mp4?title=TR+four+chamber+color+Doppler+echo+1\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four chamber view from a 2-D echocardiogram with color flow Doppler shows significant tricuspid regurgitation. There is enlargement of the left atrium and limited mobility of the mitral valve which shows doming in diastole, suggesting that tricuspid regurgitation is the result of pulmonary hypertension due to mitral stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9232=[""].join("\n");
var outline_f9_1_9232=null;
var title_f9_1_9233="Morisons pouch free fluid";
var content_f9_1_9233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound image of free fluid in Morisons pouch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image, taken from a FAST examination, shows free fluid surrounding the liver (indicated by the arrow).",
"    <div class=\"footnotes\">",
"     K: kidney; L: liver",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9233=[""].join("\n");
var outline_f9_1_9233=null;
var title_f9_1_9234="Patient information: Myelodysplastic syndromes (MDS) (The Basics)";
var content_f9_1_9234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/52/22338\">",
"         Patient information: Blood donation (giving blood) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/12/26820\">",
"         Patient information: Blood donation and transfusion (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/26/6564\">",
"         Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/myelodysplastic-syndromes-mds-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19865636\">",
"      <span class=\"h1\">",
"       What are myelodysplastic syndromes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Myelodysplastic syndromes (MDS) are a group of conditions that involve the blood. Blood is made up of different types of cells. These cells are made in the middle of the bones, in a part called the bone marrow.",
"     </p>",
"     <p>",
"      When people have MDS, their bone marrow does not work normally. It makes abnormal blood cells and does not make enough normal blood cells. This can cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19865643\">",
"      <span class=\"h1\">",
"       What are the symptoms of MDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with MDS have no symptoms. They might find out that they have MDS after they have blood tests for another reason.",
"     </p>",
"     <p>",
"      Other people do have symptoms. They might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel weak, tired, or dizzy",
"       </li>",
"       <li>",
"        Have trouble thinking clearly",
"       </li>",
"       <li>",
"        Have trouble breathing",
"       </li>",
"       <li>",
"        Bruise or bleed more easily than usual",
"       </li>",
"       <li>",
"        Get infections more easily than usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19865650\">",
"      <span class=\"h1\">",
"       Is there a test for MDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To test for MDS, your doctor or nurse can do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Bone marrow biopsy &mdash; During this procedure, a doctor removes a very small sample of the bone marrow. Then another doctor looks at the cells under a microscope to see if abnormal cells are present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are different types of MDS. Your doctor will use your test results to figure out which type you have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19865657\">",
"      <span class=\"h1\">",
"       How is MDS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment for you will depend, for the most part, on the type of MDS you have, your symptoms, and your age. Most treatments do not cure MDS. But treatments can improve symptoms and help people feel better.",
"     </p>",
"     <p>",
"      Doctors usually treat MDS with 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood transfusions &mdash; A blood transfusion is when a person gets blood that was given (donated) by another person.",
"       </li>",
"       <li>",
"        Medicines &mdash; Doctors can use different types of medicines to treat MDS. These medicines work in different ways. Some medicines help the bone marrow make more blood cells. Other medicines affect the body&rsquo;s infection-fighting system.",
"       </li>",
"       <li>",
"        Chemotherapy &mdash; Chemotherapy is the term doctors use to describe a group of medicines that kill abnormal cells.",
"       </li>",
"       <li>",
"        Bone marrow transplant &mdash; This treatment uses chemotherapy or another treatment called radiation to kill the abnormal cells in the bone marrow. These dead cells are then replaced with &ldquo;donor&rdquo; cells. The &ldquo;donor&rdquo; cells can come from different places. They usually come from people whose blood matches yours. Bone marrow transplant is the only treatment that can cure MDS.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse might also talk with you about being in a clinical trial. A clinical trial is a research study that uses volunteers to test new treatments or new combinations of current treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19865664\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=see_link\">",
"       Patient information: Blood donation (giving blood) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=see_link\">",
"       Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"       Patient information: Blood donation and transfusion (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/1/9234?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16328 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9234=[""].join("\n");
var outline_f9_1_9234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19865636\">",
"      What are myelodysplastic syndromes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19865643\">",
"      What are the symptoms of MDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19865650\">",
"      Is there a test for MDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19865657\">",
"      How is MDS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19865664\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_1_9235="Fluocinonide: Pediatric drug information";
var content_f9_1_9235=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinonide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"    see \"Fluocinonide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8452?source=see_link\">",
"    see \"Fluocinonide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vanos&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lidemol&reg;;",
"     </li>",
"     <li>",
"      Lidex&reg;;",
"     </li>",
"     <li>",
"      Lyderm&reg;;",
"     </li>",
"     <li>",
"      Tiamol&reg;;",
"     </li>",
"     <li>",
"      Topactin;",
"     </li>",
"     <li>",
"      Topsyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"      see \"Fluocinonide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical: Apply thin layer to affected area 2-4 times/day depending on the severity of the condition",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vanos&reg;: 0.1% (30 g, 60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, anhydrous, emollient, topical: 0.05% (15 g, 30 g, 60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, aqueous, emollient, topical: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 0.05% (20 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply sparingly in a thin film; rub in lightly",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inflammation of corticosteroid-responsive dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluocinonide may be confused with flunisolide, fluocinolone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lidex&reg; may be confused with Lasix&reg;, Videx&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F172367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Intracranial hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, contact dermatitis, dry skin, folliculitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, pruritus, skin atrophy, striae, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cushing's syndrome, growth retardation, HPA axis suppression, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinonide or any component; viral, fungal, or tubercular skin lesions; herpes (including varicella)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants and small children may be more susceptible to adrenal axis suppression from topical corticosteroid therapy; systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, or with occlusive dressings",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animals administered potent topical corticosteroids. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not well defined topically; possesses anti-inflammatory, antiproliferative, and immunosuppressive properties",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8452?source=see_link\">",
"      see \"Fluocinonide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not overuse; avoid contact with eyes; do not use for longer than directed; avoid use on face; notify physician if condition being treated persists or worsens",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Considered to be a high potency steroid",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13311 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9235=[""].join("\n");
var outline_f9_1_9235=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172332\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172333\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052884\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052879\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172320\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172307\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052888\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052887\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172368\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172367\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052890\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052878\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299350\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172315\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172316\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277393\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052877\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052882\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052891\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13311|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=related_link\">",
"      Fluocinonide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/16/8452?source=related_link\">",
"      Fluocinonide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_1_9236="Bullous pemphigoid vulva";
var content_f9_1_9236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9236=[""].join("\n");
var outline_f9_1_9236=null;
var title_f9_1_9237="Tension pneumothorax II PA";
var content_f9_1_9237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a tension pneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tension pneumothorax due to insertion of right-sided Swan-Ganz catheter in patient with left ventricular failure and pulmonary edema. Chest radiograph shows collapse of the right lung and cardiomediastinal silhouette to the left with marked compression of the left lung, leading to respiratory failure. The right hemidiaphragm is depressed caudad, and the right-sided rib spaces are markedly widened.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9237=[""].join("\n");
var outline_f9_1_9237=null;
var title_f9_1_9238="Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma";
var content_f9_1_9238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9238/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/1/9238/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary mediastinal large B-cell lymphoma (PMBL) is an aggressive B-cell lymphoma that is thought to arise from thymic (medullary) B-cells. It has clinicopathologic features that are distinct from other diffuse large B-cell lymphomas (DLBCL).",
"   </p>",
"   <p>",
"    This topic will discuss the clinical presentation, pathologic features, diagnosis, and differential diagnosis of PMBL. The diagnosis of systemic DLBCL is presented separately, as is the treatment of PMBL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link&amp;anchor=H17320527#H17320527\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\", section on 'Mediastinum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMBL comprises 7 percent of DLBCLs (2.4 percent of all non-Hodgkin lymphomas)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There is a female predominance and a median age at diagnosis in the third to fourth decade [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients present with a locally invasive anterior mediastinal mass originating in the thymus, with frequent airway compromise and superior vena cava (SVC) syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77617 \" href=\"UTD.htm?13/60/14272\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59806 \" href=\"UTD.htm?28/9/28816\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/4\">",
"     4",
"    </a>",
"    ]. In one report of 30 patients, for example, SVC syndrome was present in 57 percent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, other patients without clinical SVC obstruction had evidence of compression of this vessel by computed tomography (CT) scan; in total, 80 percent had some evidence of SVC compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other structures that are sometimes involved by direct extension include the lungs, pleura, and pericardium. Up to half of patients may have a pleural of pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptoms related to the compression or invasion of local structures (ie, cough, dyspnea, dysphagia, hoarseness) are common. While PMBL may spread to supraclavicular and cervical lymph nodes, by definition there is no evidence of tumor in the bone marrow or more distant lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of 153 patients found the following signs and symptoms at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated lactate dehydrogenase (LDH, 77 percent)",
"     </li>",
"     <li>",
"      Systemic B symptoms (ie, fever, night sweats, weight loss, 47 percent)",
"     </li>",
"     <li>",
"      Pleural or pericardial effusion (50 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately three-quarters of patients have stage I or II disease at the time of diagnosis, with masses greater than 10 cm (ie, bulky disease) present in the majority [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Systemic complaints (B symptoms)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapses tend to be extranodal, including the liver, gastrointestinal tract, kidneys, ovaries, and central nervous system. Although early studies suggested an unusually aggressive, incurable malignancy, more recent studies have reported cure rates similar to those for typical DLBCL with aggressive therapy, usually combining chemotherapy with mediastinal irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/3,5,8\">",
"     3,5,8",
"    </a>",
"    ]. However, if progression or relapse occurs, salvage therapy is rarely curative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link&amp;anchor=H17320527#H17320527\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\", section on 'Mediastinum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMBL usually involves the thymus at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The tumor is composed of large cells with variable nuclear features, resembling centroblasts, large centrocytes, or multilobated cells, often with pale or \"clear\" cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/7\">",
"     7",
"    </a>",
"    ]. Less frequently, the tumor cells resemble immunoblasts. Reed-Sternberg-like cells may be present. Many cases have fine, compartmentalizing sclerosis (",
"    <a class=\"graphic graphic_picture graphicRef53317 \" href=\"UTD.htm?39/45/40663\">",
"     picture 1",
"    </a>",
"    ). For more details on the morphology of centrocytes, centroblasts, and immunoblasts, please see our topic on DLBCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor cells do not express immunoglobulin, CD5, or CD10, but express B-cell-associated antigens (CD19, CD20, CD22, CD79a) and CD45 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/10\">",
"     10",
"    </a>",
"    ]. Expression of CD30 is often present, but weak. The tumor cells also stain for TRAF-1 and nuclear c-Rel [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/11\">",
"     11",
"    </a>",
"    ]. These two markers are also commonly expressed by the Reed-Sternberg cells of classical Hodgkin lymphoma, but are uncommonly present in other forms of DLBCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin heavy and light chain genes are rearranged. The B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (BCL-2) gene is usually germline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ] and B cell leukemia 6 (BCL-6) gene rearrangements are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/14\">",
"     14",
"    </a>",
"    ]. Amplification of the REL oncogene has been described in a minority of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/15\">",
"     15",
"    </a>",
"    ]. Hyperdiploid karyotypes, often with gains in the region containing the JAK2 gene on chromosome 9p, have been noted. Gene expression profiling has shown a similarity between the cell lines of primary mediastinal large B-cell lymphoma and classical Hodgkin lymphoma, a disorder with which it shares a number of clinical and laboratory features [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Obtaining tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most difficult problems in the diagnosis of PMBL can be obtaining an adequate biopsy specimen. Biopsies may be non-diagnostic because the lesion is not sampled adequately or because crush artifact or extensive necrosis, fibrosis, or cystic change obscures the diagnostic lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnostic biopsy should obtain the largest sample of tissue that can be easily and safely acquired. Due to fibrosis (which is often extensive), needle aspirates are often paucicellular and do not provide sufficient numbers of well preserved tumor cells to establish the diagnosis. Similarly, core biopsies often contain only fibrotic tissue of tumor cells that are disrupted and not diagnostically useful. As such, a surgical biopsy is preferred. The most common methods used for surgical biopsy of the mediastinum include cervical mediastinoscopy, anterior mediastinotomy, or thoracoscopy, depending upon the location of the lesion. Intraoperative frozen sections are often used to determine if diagnostic tissue has been obtained. However, frozen section processing introduces artifacts, and additional tissue should also be obtained that is not processed for frozen sectioning. A sample of tumor may be set aside to be snap frozen for molecular analyses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation of the patient with suspected PMBL includes imaging with a positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    scan or CT scan and a bone marrow biopsy to determine extent of disease. Patients with involvement of the bone marrow or distant lymph nodes likely have systemic lymphoma with secondary mediastinal involvement, rather than PMBL. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Systemic lymphoma with secondary mediastinal involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PMBL is based on an evaluation of the tumor morphology and immunophenotyping interpreted in the context of the clinical presentation. As mentioned above, patients with PMBL may have locally extensive disease, but usually do not have evidence of distant spread at initial presentation. Staining for pan-B cell markers, such as CD20 and CD79a is sufficient to establish the diagnosis in many cases; additional stains for CD30, nuclear Rel, and TRAF-1 can be helpful in cases with atypical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PMBL includes benign and malignant mediastinal tumors and, less commonly, infectious and inflammatory entities that may present with mediastinal involvement (eg, histoplasmosis and Castleman's disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic lymphoma with secondary mediastinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic diffuse large B-cell lymphoma (DLBCL) tend to be older with a median age at diagnosis in the seventh decade, but this entity can be seen in younger adults and children. Systemic DLBCL occasionally presents with mediastinal involvement and may be confused with PMBL. As mentioned above, part of the evaluation of a patient with suspected PMBL should include imaging studies and a bone marrow biopsy. At diagnosis, PMBL may have spread to supraclavicular and cervical lymph nodes, and late in its course it has a curious propensity to involve viscera (eg, the kidney) and the central nervous system (CNS). However, if there is evidence of tumor in the bone marrow or involvement of more distant lymph nodes, the more likely diagnosis is systemic DLBCL with secondary mediastinal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/7\">",
"     7",
"    </a>",
"    ]. As mentioned above, immunohistochemistry can also help distinguish between systemic DLBCL and PMBL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL) and PMBL share many clinical and pathologic features. They are both more common in young women and present with a large mediastinal mass. On biopsy, PMBL may have cells that resemble the neoplastic Reed-Sternberg cells of HL. In addition, gene expression profiling has shown a similarity between the two entities.",
"   </p>",
"   <p>",
"    Immunophenotype can help to distinguish PMBL from HL most cases. In classical HL, the neoplastic Reed-Sternberg cells typically express CD15 (85 percent of cases) and CD30 (&gt;95 percent of cases, usually bright), and lack pan-B and pan-T antigens. In contrast, PMBL cells typically express pan-B cell antigens, have weak expression of CD30, and only rarely express CD15. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are occasional cases that combine features of PMBL and classical HL. Such cases are labeled \"B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9238/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary large B-cell lymphoma (PMBL) of the mediastinum is an aggressive tumor arising in the mediastinum from the thymic (medullary) B-cell. It is a distinct clinicopathologic entity that differs from systemic DLBCL.",
"     </li>",
"     <li>",
"      PMBL typically affects persons in their third to fourth decade of life and has a female predominance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients present with a locally invasive anterior mediastinal mass with frequent invasion of local structures resulting in superior vena cava syndrome, effusions, and symptoms of cough, dyspnea, dysphagia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hoarseness. Systemic B symptoms and elevated lactate dehydrogenase levels are not uncommon. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tumor is composed of large cells with variable nuclear features, resembling centroblasts, large centrocytes, or multilobated cells, often with pale or \"clear\" cytoplasm. The tumor cells typically express B-cell-associated antigens (CD19, CD20, CD22, CD79a), CD45, and CD30 (weak), and typically fail to express immunoglobulin, CD5, and CD10. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining an adequate biopsy specimen is key to the diagnosis. A surgical biopsy is preferred to needle aspirates and core biopsies, since the latter often do not provide sufficient numbers of well-preserved cells. Further evaluation involves imaging studies and a bone marrow biopsy. The diagnosis is ultimately made based on an evaluation of the tumor morphology and immunophenotyping interpreted in the context of the clinical presentation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of PMBL includes benign and malignant tumors that present in the anterior mediastinum. The most difficult pathologic distinctions involve systemic lymphoma with secondary mediastinal involvement and Hodgkin lymphoma. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/1\">",
"      A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/2\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/3\">",
"      Nguyen LN, Ha CS, Hess M, et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys 2000; 47:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/4\">",
"      van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/5\">",
"      Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 1988; 62:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/6\">",
"      Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/8\">",
"      Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/9\">",
"      Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 1986; 10:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/10\">",
"      Lamarre L, Jacobson JO, Aisenberg AC, Harris NL. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol 1989; 13:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/11\">",
"      Rodig SJ, Savage KJ, Nguyen V, et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 2005; 29:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/12\">",
"      M&ouml;ller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood 1987; 69:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/13\">",
"      Scarpa A, Bonetti F, Menestrina F, et al. Mediastinal large-cell lymphoma with sclerosis. Genotypic analysis establishes its B nature. Virchows Arch A Pathol Anat Histopathol 1987; 412:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/14\">",
"      Tsang P, Cesarman E, Chadburn A, et al. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol 1996; 148:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/15\">",
"      Joos S, Ota&ntilde;o-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996; 87:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/16\">",
"      Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/17\">",
"      Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102:3871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9238/abstract/18\">",
"      Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104:543.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4713 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9238=[""].join("\n");
var outline_f9_1_9238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Obtaining tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic lymphoma with secondary mediastinal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4713|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/60/14272\" title=\"diagnostic image 1\">",
"      Mediastinal lymphoma PA and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/9/28816\" title=\"diagnostic image 2\">",
"      SVC syndrome mediast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4713|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/45/40663\" title=\"picture 1\">",
"      Mediastinal lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_1_9239="Bilateral port wine stains in SWS";
var content_f9_1_9239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73343%7EDERM%2F60560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73343%7EDERM%2F60560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral port wine stains in a child with Sturge-Weber syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral port wine stains are present on the face of this patient with Sturge-Weber syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sturge-Weber syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral port wine stains involving V1 are present on this infant with Sturge-Weber syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9239=[""].join("\n");
var outline_f9_1_9239=null;
var title_f9_1_9240="Metabolism of adrenal steroids";
var content_f9_1_9240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metabolism of adrenal steroids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9240/contributors\">",
"     William J Kovacs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9240/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9240/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/1/9240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The actions of glucocorticoids can be terminated by conversion of these steroids to biologically inactive forms. The processes by which these steroids are inactivated involve a number of enzymes and tissues. The importance of alterations in the metabolic degradation of adrenal steroids in human physiology and disease states is becoming increasingly clear and will be reviewed here.",
"    <br/>",
"    <br/>",
"    Adrenal steroid biosynthesis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID METABOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818315\">",
"    <span class=\"h2\">",
"     Hepatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major site of cortisol metabolism is the liver. There cortisol is reduced, oxidized, or hydroxylated, and the products of these reactions are made water soluble by conjugation with sulfate or glucuronic acid to facilitate their excretion in urine (",
"    <a class=\"graphic graphic_figure graphicRef79190 \" href=\"UTD.htm?3/46/3818\">",
"     figure 1",
"    </a>",
"    ). Gas chromatography with mass spectrometry",
"    <span class=\"nowrap\">",
"     (GC/MS)",
"    </span>",
"    has provided quantitative data on the urinary excretion of each of these cortisol metabolites, allowing identification of a number of inherited and acquired disorders characterized by abnormal glucocorticoid dynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol is inactivated mainly by reductive disruption of its 3-keto, delta-4 double bond structure. Reduction reactions can also result in &ldquo;regeneration&rdquo; of cortisol from its inactive metabolite, cortisone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction of the keto group, with formation of a 3-hydroxyl group, is carried out by 3 alpha hydroxysteroid dehydrogenase.",
"     </li>",
"     <li>",
"      Reduction of the cortisol A ring double bond, which results in an asymmetric carbon atom at position 5, is carried out by 5 alpha-reductase (of which there are two isoforms expressed in liver) and 5 beta-reductase.",
"     </li>",
"     <li>",
"      The 5 alpha-reductase type 1 enzyme, encoded by a gene (SRD5A1) on the distal short arm of chromosome 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/2,3\">",
"       2,3",
"      </a>",
"      ], is expressed in skin, adipose tissue, and liver in adult humans, and exhibits maximal activity at alkaline pH [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The type 2 5 alpha-reductase is encoded by a gene (SRD5A2) on the short arm of chromosome 2 and functions at an acidic pH optimum. SRD5A2 is expressed in tissues of the reproductive tract, where it amplifies the actions of testosterone, as well as in the liver where its reduction of the cortisol A ring inactivates the hormone.",
"     </li>",
"     <li>",
"      The 5 beta-reductase enzyme is encoded by a single gene (AKR1D1) on the long arm of chromosome 7 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/6\">",
"       6",
"      </a>",
"      ]. This gene is a member of the aldo-keto reductase family, a group of related NAD(P)H-dependent oxidoreductases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/7\">",
"       7",
"      </a>",
"      ]. The enzyme's substrate specificities suggest a primary role in bile acid synthesis rather than cortisol metabolism but no other gene encoding an enzyme with 5 beta-reductase activity has been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/8\">",
"       8",
"      </a>",
"      ] and detailed studies of a 13-year-old patient with a homozygous missense mutation in AKR1D1 revealed nearly total absence of 5 beta reduced metabolites of cortisol and cortisone in urine [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/9\">",
"       9",
"      </a>",
"      ]. In normal men and women, 5 beta tetrahydrocortisol is slightly more abundant in urine than 5 alpha tetrahydrocortisol.",
"     </li>",
"     <li>",
"      In healthy individuals, the majority of urinary glucocorticoid metabolites have been reduced at both the 3 keto group (by 3 alpha-hydroxysteroid dehydrogenase) and at the 4-5 double bond in the A ring (by 5 alpha or 5 beta reductases). These tetrahydro- derivatives of cortisol and cortisone compromise more than 66 percent of urinary glucocorticoid metabolites in both women and men.",
"     </li>",
"     <li>",
"      The tetrahydrocortisols and tetrahydrocortisone produced by the actions of the 5",
"      <span class=\"nowrap\">",
"       alpha/5",
"      </span>",
"      beta reductases and 3 alpha-hydroxysteroid dehydrogenases can be further reduced at the 20-ketone (by 20-hydroxysteroid dehydrogenases) to yield the cortols and cortolones. These cortols and cortolones make up about 20 percent of total urine glucocorticoid metabolites.",
"     </li>",
"     <li>",
"      11 beta-hydroxysteroid dehydrogenase type I (11 beta-HSD-1) is a key enzyme in cortisol metabolism, with both dehydrogenase and reductase activities. It is constitutively expressed in liver, adipose tissue, bone, and central nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/10-12\">",
"       10-12",
"      </a>",
"      ], but is also inducible in a variety of other tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/12\">",
"       12",
"      </a>",
"      ]. While the enzyme has the capacity to inactivate cortisol by oxidation, the reverse (reductase) reaction (ie, conversion of cortisone to cortisol) normally predominates in the liver in vivo.",
"      <br/>",
"      <br/>",
"      The reductase directionality of 11 beta-HSD-1's catalysis is determined by the co-expression of an NADPH-generating system, hexose-6-phosphate dehydrogenase, which maintains a reducing environment within the endoplasmic reticulum where 11 beta-HSD-1 is localized [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In normal subjects, urinary 11-keto (cortisone) metabolites are slightly more abundant than 11-hydroxy (cortisol) metabolites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Oxidation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol and its metabolites are also oxidized in the liver. Oxidative removal of the C20, C21 side chain yields a C19 steroid with a 17-ketone group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/14\">",
"     14",
"    </a>",
"    ]. Available evidence indicates that this side chain cleavage is not carried out by CYP17, the enzyme that catalyzes this reaction in androgen biosynthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/15\">",
"     15",
"    </a>",
"    ]. The identity of the gene encoding this side chain cleavage enzyme activity is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hydroxylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;6 beta-hydroxylation of cortisol occurs in the liver by the CYP3A4 enzyme, but only to a minor extent, with 6 beta-hydroxycortisol accounting for less than 3 percent of total urinary glucocorticoid metabolites. When serum cortisol concentrations are high, as in patients with Cushing's syndrome, disproportionately large amounts of 6 beta-hydroxycortisol may be produced and excreted in the urine, possibly because of saturation of the reduction and oxidation pathways, but also perhaps because of induction of CYP3A4 by hypercortisolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Conjugation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The C19 and C21 metabolites of cortisol are more water-soluble when conjugated to glucuronic acid or sulfate, primarily the former. Glucuronidation is catalyzed by one of the uridine diphosphoglucuronosyl transferases, enzymes that catalyze the glucuronidation of xenobiotics, bilirubin, and steroids in the endoplasmic reticulum of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/18\">",
"     18",
"    </a>",
"    ]. Specific isoenzymes act on different substrates, even among the steroid hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Glucuronide may be conjugated to any hydroxyl group, but the 3 alpha-hydroxyl is preferred. Most tetrahydrocortisol derivatives are excreted in the urine as glucuronides.",
"   </p>",
"   <p>",
"    Sulfation is catalyzed by cytosolic sulfotransferases. Only a small fraction of 3 alpha-hydroxysteroid metabolites, but most of the 3 beta-hydroxysteroids (both C19 and C21), are conjugated with sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/21\">",
"     21",
"    </a>",
"    ]. While these conjugation reactions have generally been considered as \"Phase II\" metabolic processes that follow reduction reactions, evidence now suggests that conjugated steroids may, in fact, serve as substarters for some aldo-keto-reductase enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alterations in hepatic metabolism of cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors and conditions are associated with altered hepatic metabolism of cortisol, including hormones, age, disease, obesity, and drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Hormones",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid hormone alters cortisol metabolism. In patients with hyperthyroidism, cortisol clearance is accelerated, but serum cortisol concentrations are normal because of a compensatory increase in cortisol secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/23\">",
"       23",
"      </a>",
"      ]. Conversely, in patients with hypothyroidism, cortisol clearance is slowed and urinary excretion of cortisol metabolites is decreased, but serum cortisol concentrations still are normal. These changes in the rate of cortisol secretion occur because the hypothalamic-pituitary-adrenal axis is normal, and changes in serum cortisol concentrations elicit compensatory changes in the secretion of corticotropin. The effect of thyroid hormone is due largely to an increase in hepatic 5 alpha- and 5 beta-reductase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are some differences in cortisol metabolism between men and women. Women excrete relatively less 5 alpha- and 5 beta-tetrahydrocortisol than men, but similar quantities of cortisol, cortisone, and tetrahydrocortisone [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/25\">",
"       25",
"      </a>",
"      ]. Hormonal changes of the menstrual cycle do not appear to influence cortisol metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/25\">",
"       25",
"      </a>",
"      ]. Hepatic conversion of cortisone to cortisol is not different between sexes.",
"     </li>",
"     <li>",
"      In patients with Cushing's syndrome, 6 beta-hydroxylation of steroids is increased [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/16\">",
"       16",
"      </a>",
"      ], and proportionally smaller amounts of cortols, cortolones, tetrahydrocortisone, and 5 alpha-tetrahydrocortisol are excreted [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/26\">",
"       26",
"      </a>",
"      ]. Glucocorticoids also stimulate hepatic 11 beta-hydroxysteroid dehydrogenase activity, while insulin and insulin-like growth factor-1 inhibit it [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperinsulinemia accompanying states of insulin resistance is associated with increases in 5 alpha-reductase activity (presumably hepatic) as assessed by urinary excretion of 5 alpha-reduced metabolites of cortisol. This relationship is observed in both men and women, and is independent of body weight or fat mass [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/28\">",
"       28",
"      </a>",
"      ]. Improvements in insulin sensitivity after weight loss result in reduction of 5 alpha-reductase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Age and disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of age and disease on the hepatic metabolism of cortisol include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of metabolism of cortisol and urinary excretion of 17-hydroxycorticosteroids (tetrahydrocortisols, tetrahydrocortisone) decrease with age [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/30\">",
"       30",
"      </a>",
"      ], but serum cortisol concentrations do not.",
"     </li>",
"     <li>",
"      Enzymatic metabolism of cortisol usually is normal in patients with renal disease, but clearance of glucuronides is diminished so that these inactive compounds may accumulate in serum [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with polycystic ovary syndrome (PCOS) have increased 5 alpha-reductase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/31\">",
"       31",
"      </a>",
"      ]. This increase in cortisol metabolism was observed in lean women with PCOS.",
"      <br/>",
"      <br/>",
"      Patients with cirrhosis have a reduction of both 5 alpha- and 5 beta-reductase activities, but 3 alpha-hydroxysteroid dehydrogenase and glucuronosyl transferase activities remain normal [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/32\">",
"       32",
"      </a>",
"      ]. Men with fatty liver have been reported to have increased 5 beta-reductase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/33\">",
"       33",
"      </a>",
"      ] with a decrease in hepatic 11&beta;-HSD1 activity and an increase in total cortisol metabolites [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/34\">",
"       34",
"      </a>",
"      ]. With progression to with NASH, 11&beta;-HSD1 activity was increased both in comparison to patients with steatosis, and controls [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Obesity and Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese subjects excrete significantly greater amounts of cortisol metabolites than do lean subjects. This difference persists even when the values are normalized for body surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The cortisol production rate is increased in obese subjects, however, so that their serum cortisol concentrations are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/32\">",
"     32",
"    </a>",
"    ]. In obese men, a low carbohydrate diet reverses this increase in hepatic clearance of cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs affect hepatic cortisol metabolism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adrenocorticolytic drug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      increases 6-beta-hydroxylation, but does not increase the overall metabolism of cortisol. Mitotane does accelerate the metabolism of halogenated synthetic steroids, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      , and 9 alpha-fluorohydrocortisone.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      have a similar effect [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The antituberculous drug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      accelerates the metabolism of both synthetic steroids (including 9 alpha-fluorohydrocortisone) and cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/40-42\">",
"       40-42",
"      </a>",
"      ], and urinary 6 beta-hydroxycortisol excretion is increased in rifampin-treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       Cimetidine",
"      </a>",
"      inhibits hepatic CYP (cytochrome P450) enzymes, but it has no effect on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Troglitazone, a thiazolidinedione that is no longer marketed for therapeutic use is a potent inducer of CYP3A4 (6 beta-hydroxylase) and accelerates",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      metabolism sufficiently to alter dexamethasone suppression test results.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       Rosiglitazone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      do not appear to have such CYP3A4 induction activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Extrahepatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney is a major site of extrahepatic cortisol metabolism in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/47\">",
"     47",
"    </a>",
"    ]. There, cortisol is converted to cortisone by the high-affinity, NAD-dependent form (type 2) of 11 beta-hydroxysteroid dehydrogenase that is encoded by a gene on chromosome 16q22 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This conversion reduces cortisol access to the mineralocorticoid receptor (MR) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], which otherwise binds cortisol and aldosterone with equal affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/52\">",
"     52",
"    </a>",
"    ]. Restricting cortisol access to MR therefore allows aldosterone to exert its physiologic effects. Genetic or pharmacologic impairment of 11 beta-hydroxysteroid dehydrogenase type 2 results in cortisol-mediated mineralocorticoid effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The enzyme 11 beta hydroxysteroid dehydrogenase type 1 is not restricted to hepatic expression, but is found in many, perhaps all, glucocorticoid target tissues, including pituitary corticotrophs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/53\">",
"     53",
"    </a>",
"    ]. It plays a major role in regulating the concentration of cortisol to which target cells are exposed. Transgenic mice overexpressing this enzyme in adipose tissue developed obesity and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/54\">",
"     54",
"    </a>",
"    ], suggesting that local conversion of cortisone to cortisol in visceral fat might contribute to these conditions. The role of 11 beta-hydroxysteroid dehydrogenase, type I in production of the phenotypic features of the human metabolic syndrome is less certain, and has been an area of active inquiry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/55\">",
"     55",
"    </a>",
"    ]. In human subjects, the production of cortisol by 11 beta-hydroxysteroid dehydrogenase, type I in adipose tissue has been found to be quantitatively negligible compared to hepatic production of cortisol by this enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While increased adipose tissue expression of 11 beta hydroxysteroid dehydrogenase type I is observed in subjects with insulin resistance and impaired glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/28\">",
"     28",
"    </a>",
"    ], it has also been found that weight loss after gastric bypass surgery in obese, insulin resistant women results in significant reduction in expression of 11-beta hydroxysteroid dehydrogenase in adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/59\">",
"     59",
"    </a>",
"    ]. These data have raised the question of whether increases in adipose tissue 11 beta hydroxysteroid dehydrogenase activity are a consequence, rather than a cause of obesity and insulin resistance.",
"   </p>",
"   <p>",
"    11 beta hydroxysteroid dehydrogenase type I is expressed in the cells of the immune system, including developing thymocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The enzyme is further induced in T cells by receptor-mediated activation. A physiologic role for paracrine or autocrine actions of glucocorticoids generated in immune cells is yet to be defined.",
"   </p>",
"   <p>",
"    In the brain 11 beta-hydroxysteroid dehydrogenase type I is involved in the age-related decline in learning and memory tasks in mice; rodents lacking the enzyme appear protected from the decline in the brain function observed with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/55\">",
"     55",
"    </a>",
"    ]. The enzyme is also expressed in human brain; whether modulation of its function could impact human brain function is not known.",
"   </p>",
"   <p>",
"    Additional mechanisms may exist for terminating the actions of steroid hormones within target tissue cells. Glucuronidase activity is found in many human and monkey tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/63\">",
"     63",
"    </a>",
"    ]. The uridine diphosphoglucuronosyl transferase enzymes in these tissues metabolize primarily androgens and estrogens, but these and other enzymes that metabolize glucocorticoids and mineralocorticoids presumably are found in their target tissue cells and may play an important role in terminating steroid hormone action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ALDOSTERONE METABOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone, like cortisol, is reduced predominantly by a hepatic delta-4, 3-ketosteroid reductase, and a 3 alpha-hydroxysteroid dehydrogenase (",
"    <a class=\"graphic graphic_figure graphicRef79190 \" href=\"UTD.htm?3/46/3818\">",
"     figure 1",
"    </a>",
"    ). The cytosolic delta-4-reductase also has 5 beta-hydroxysteroid reductase activity, so that the major metabolic product is 3 alpha, 5-beta-tetrahydroaldosterone. This metabolite, in the form of tetrahydroaldosterone glucuronide, accounts for 35 to 40 percent of the aldosterone metabolites in urine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/64\">",
"     64",
"    </a>",
"    ]. A 21-deoxy form of tetrahydroaldosterone is further reduced to the 20-alpha-hydroxy form [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/65\">",
"     65",
"    </a>",
"    ]. The 20-alpha-hydroxyl group can condense with the hydroxyl of the C18 hemiacetal to form an aldosterone metabolite with bicyclic acetal rings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Conjugation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetrahydroaldosterone is conjugated to glucuronic acid in the liver at the 3-keto position, and tetrahydroaldosterone glucuronide is the major urinary metabolite of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/67\">",
"     67",
"    </a>",
"    ]. Another conjugate, aldosterone-18-glucuronide, is produced by direct conjugation of unreduced aldosterone and accounts for approximately 10 percent of the aldosterone metabolites excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alterations in aldosterone metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cirrhosis and ascites, the production rate and serum concentration of aldosterone are often high as a result of increased plasma renin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/32\">",
"     32",
"    </a>",
"    ]. The ability of the liver to metabolize aldosterone is impaired, so a greater fraction is metabolized extrahepatically [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Patients with severe congestive heart failure and impaired perfusion of the liver also have impaired aldosterone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/71\">",
"     71",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    results in inhibition of the enzyme responsible for 18-glucuronidation of aldosterone. The elevated aldosterone levels observed in spironolactone-treated subjects may reflect, at least in part, this inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADRENAL ANDROGEN METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steroid produced in greatest quantity by the adrenal cortex and its major C19 androgenic product is dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA sulfate). Most of the DHEA is converted to androstenedione by oxidation of the 3 beta-hydroxyl group and isomerization of the delta-5 double bond to the delta-4 position. Androstenedione is reduced by 5 alpha-reductase to yield androsterone and etiocholanolone, which are then reduced by 17-beta-hydroxysteroid dehydrogenase to yield the respective -diol derivatives, followed by conjugation and excretion in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DHEA sulfate can be directly excreted in the urine; the sulfate group can be hydrolyzed to yield free DHEA, which is metabolized as just described, or DHEA sulfate can be metabolized by 16- or 17-hydroxylation or by reversible 17-beta-reduction to yield androstenediol sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/73\">",
"     73",
"    </a>",
"    ]. DHEA sulfate and its metabolites are cleared more slowly from serum by the kidney than their nonsulfated analogues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/73\">",
"     73",
"    </a>",
"    ]. Fecal excretion of DHEA and its metabolites is quantitatively more important than for other steroids; 30 to 45 percent of the metabolites of DHEA sulfate may be excreted via the biliary tract and appear in the feces [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9240/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=see_link\">",
"     \"Measurement of adrenal androgens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239061040\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The actions of glucocorticoids can be terminated by conversion of these steroids to biologically inactive forms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major site of cortisol metabolism is the liver. There, cortisol is reduced or oxidized and hydroxylated, and the products of these reactions are made water soluble by conjugation with sulfate or glucuronic acid to facilitate their excretion in urine (",
"      <a class=\"graphic graphic_figure graphicRef79190 \" href=\"UTD.htm?3/46/3818\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glucocorticoid metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several factors and conditions are associated with altered hepatic metabolism of cortisol, including thyroid hormone, age, liver or kidney disease, obesity, and drugs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Alterations in hepatic metabolism of cortisol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The liver is also the major site of aldosterone metabolism. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Aldosterone metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The steroid produced in greatest quantity by the adrenal cortex and its major C19 androgenic product is dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA sulfate). Most of the DHEA is converted to androstenedione. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Adrenal androgen metabolism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/1\">",
"      Shackleton CH. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol 1993; 45:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/2\">",
"      Jenkins EP, Hsieh CL, Milatovich A, et al. Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991; 11:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/3\">",
"      Thigpen AE, Russell DW. Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem 1992; 267:8577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/4\">",
"      Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993; 92:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/5\">",
"      Wake DJ, Strand M, Rask E, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007; 66:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/6\">",
"      Charbonneau A, Luu-The V. Assignment of steroid 5beta-reductase (SRD5B1) and its pseudogene (SRD5BP1) to human chromosome bands 7q32--&gt;q33 and 1q23--&gt;q25, respectively, by in situ hybridization. Cytogenet Cell Genet 1999; 84:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/7\">",
"      Jez JM, Flynn TG, Penning TM. A nomenclature system for the aldo-keto reductase superfamily. Adv Exp Med Biol 1997; 414:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/8\">",
"      Kondo KH, Kai MH, Setoguchi Y, et al. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. Eur J Biochem 1994; 219:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/9\">",
"      Palermo M, Marazzi MG, Hughes BA, et al. Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 2008; 73:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/10\">",
"      Napolitano A, Voice MW, Edwards CR, et al. 11Beta-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 1998; 64:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/11\">",
"      Pag&eacute; N, Warriar N, Govindan MV. 11 beta-hydroxysteroid dehydrogenase activity in human lung cells and transcription regulation by glucocorticoids. Am J Physiol 1994; 267:L464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/12\">",
"      Cooper MS, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009; 94:4645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/13\">",
"      Bujalska IJ, Draper N, Michailidou Z, et al. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. J Mol Endocrinol 2005; 34:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/14\">",
"      SANDBERG AA, CHANG E, SLAUNWHITE WR Jr. The conversion of 4-C14-cortisol to C14-17-ketosteroids. J Clin Endocrinol Metab 1957; 17:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/15\">",
"      Shackleton CH, Neres MS, Hughes BA, et al. 17-Hydroxylase/C17,20-lyase (CYP17) is not the enzyme responsible for side-chain cleavage of cortisol and its metabolites. Steroids 2008; 73:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/16\">",
"      Voccia E, Saenger P, Peterson RE, et al. 6 beta-Hydroxycortisol excretion in hypercortisolemic states. J Clin Endocrinol Metab 1979; 48:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/17\">",
"      Gibson GG, Plant NJ, Swales KE, et al. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/18\">",
"      Siest G, Antoine B, Fournel S, et al. The glucuronosyltransferases: what progress can pharmacologists expect from molecular biology and cellular enzymology? Biochem Pharmacol 1987; 36:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/19\">",
"      Falany CN, Green MD, Tephly TR. The enzymatic mechanism of glucuronidation catalyzed by two purified rat liver steroid UDP-glucuronosyltransferases. J Biol Chem 1987; 262:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/20\">",
"      Falany CN, Green MD, Swain E, Tephly TR. Substrate specificity and characterization of rat liver p-nitrophenol, 3 alpha-hydroxysteroid and 17 beta-hydroxysteroid UDP-glucuronosyltransferases. Biochem J 1986; 238:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/21\">",
"      Strott CA. Steroid sulfotransferases. Endocr Rev 1996; 17:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/22\">",
"      Jin Y, Duan L, Lee SH, et al. Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism. J Biol Chem 2009; 284:10013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/23\">",
"      PETERSON RE. The influence of the thyroid on adrenal cortical function. J Clin Invest 1958; 37:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/24\">",
"      McGUIRE JS Jr, TOMKINS GM. The effects of thyroxin administration on the enzymic reduction of delta 4-3-ketosteroids. J Biol Chem 1959; 234:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/25\">",
"      Finken MJ, Andrews RC, Andrew R, Walker BR. Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases. J Clin Endocrinol Metab 1999; 84:3316.",
"     </a>",
"    </li>",
"    <li>",
"     Peterson RE. Metabolism of adrenal cortical steroids. In: The Human Adrenal Cortex, Christy NP (Ed), Harper and Row, New York 1971. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/27\">",
"      Voice MW, Seckl JR, Edwards CR, Chapman KE. 11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem J 1996; 317 ( Pt 2):621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/28\">",
"      Tomlinson JW, Finney J, Gay C, et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008; 57:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/29\">",
"      Tomlinson JW, Finney J, Hughes BA, et al. Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes 2008; 57:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/30\">",
"      WEST CD, BROWN H, SIMONS EL, et al. Adrenocortical function and cortisol metabolism in old age. J Clin Endocrinol Metab 1961; 21:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/31\">",
"      Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 alpha-reductase activity in polycystic ovary syndrome. Lancet 1990; 335:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/32\">",
"      PETERSON RE. Adrenocortical steroid metabolism and adrenal cortical function in liver disease. J Clin Invest 1960; 39:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/33\">",
"      Westerbacka J, Yki-J&auml;rvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003; 88:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/34\">",
"      Ahmed A, Rabbitt E, Brady T, et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One 2012; 7:e29531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/35\">",
"      MIGEON CJ, GREEN OC, ECKERT JP. STUDY OF ADRENOCORTICAL FUNCTION IN OBESITY. Metabolism 1963; 12:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/36\">",
"      Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998; 83:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/37\">",
"      Stimson RH, Johnstone AM, Homer NZ, et al. Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men. J Clin Endocrinol Metab 2007; 92:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/38\">",
"      WERK EE Jr, MACGEE J, SHOLITON LJ. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest 1964; 43:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/39\">",
"      BURSTEIN S, KLAIBER EL. PHENOBARBITAL-INDUCED INCREASE IN 6-BETA-HYDROXYCORTISOL EXCRETION: CLUE TO ITS SIGNIFICANCE IN HUMAN URINE. J Clin Endocrinol Metab 1965; 25:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/40\">",
"      Edwards OM, Courtenay-Evans RJ, Galley JM, et al. Changes in cortisol metabolism following rifampicin therapy. Lancet 1974; 2:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/41\">",
"      Baciewicz AM, Self TH, Bekemeyer WB. Update on rifampin drug interactions. Arch Intern Med 1987; 147:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/42\">",
"      Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984; 59:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/43\">",
"      Yamada S, Iwai K. Letter: Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet 1976; 2:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/44\">",
"      Sirgo MA, Rocci ML Jr, Ferguson RK, et al. Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Clin Pharmacol Ther 1985; 37:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/45\">",
"      Peden NR, Rewhorn I, Champion MC, et al. Cortisol and dexamethasone elimination during treatment with cimetidine. Br J Clin Pharmacol 1984; 18:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/46\">",
"      Dimaraki EV, Jaffe CA. Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab 2003; 88:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/47\">",
"      Whitworth JA, Stewart PM, Burt D, et al. The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 1989; 31:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/48\">",
"      Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105:R11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/49\">",
"      Agarwal AK, Rogerson FM, Mune T, White PC. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics 1995; 29:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/50\">",
"      Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/51\">",
"      Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/52\">",
"      Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/53\">",
"      Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/54\">",
"      Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/55\">",
"      Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 2004; 15:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/56\">",
"      Basu R, Basu A, Grudzien M, et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009; 58:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/57\">",
"      Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009; 58:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/58\">",
"      Stewart PM, Tomlinson JW. Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both? Diabetes 2009; 58:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/59\">",
"      Simonyte K, Olsson T, N&auml;slund I, et al. Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11beta-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue. J Clin Endocrinol Metab 2010; 95:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/60\">",
"      Nuotio-Antar AM, Hasty AH, Kovacs WJ. Quantitation and cellular localization of 11beta-HSD1 expression in murine thymus. J Steroid Biochem Mol Biol 2006; 99:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/61\">",
"      Thieringer R, Le Grand CB, Carbin L, et al. 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 2001; 167:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/62\">",
"      Zhang TY, Ding X, Daynes RA. The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J Immunol 2005; 174:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/63\">",
"      Albert C, Barbier O, Vall&eacute;e M, et al. Distribution of uridine diphosphate-glucuronosyltransferase (UGT) expression and activity in cynomolgus monkey tissues: evidence for differential expression of steroid-conjugating UGT enzymes in steroid target tissues. Endocrinology 2000; 141:2472.",
"     </a>",
"    </li>",
"    <li>",
"     Melby JC. Intermediary metabolism of aldosterone. In: Handbook of Experimental Pharmacology, Page IH, Bumpus FN (Eds), Springer-Verlag, New York 1973. Vol 37, p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/65\">",
"      KELLY WG, BANDI L, LIEBERMAN S. ISOLATION AND CHARACTERIZATION OF HUMAN URINARY METABOLITES OF ALDOSTERONE. V. DIHYDROALDOSTERONE AND 21-DEOXYTETRAHYDROALDOSTERONE. Biochemistry 1963; 2:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/66\">",
"      KELLY WG, BANDI L, LIEBERMAN S. ISOLATION AND CHARACTERIZATION OF HUMAN URINARY METABOLITES OF ALDOSTERONE. IV. THE SYNTHESIS AND STEREOCHEMISTRY OF TWO BICYCLIC ACETAL METABOLITES. Biochemistry 1963; 2:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/67\">",
"      ULICK S, LARAGH JH, LIEBERMAN S. The isolation of a urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man. Trans Assoc Am Physicians 1958; 71:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/68\">",
"      AXELRAD BJ, CATES JE, JOHNSON BB, LUETSCHER JA Jr. Aldosterone in urine of normal man and of patients with oedema; its increased recovery after hydrolysis with acid and with beta-glucuronidase. Br Med J 1955; 1:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/69\">",
"      COPPAGE WS Jr, ISLAND DP, COONER AE, LIDDLE GW. The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis. J Clin Invest 1962; 41:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/70\">",
"      Bledsoe T, Liddle GW, Riondel A, et al. Comparative fates of intravenously and orally administered aldosterone: evidence for extrahepatic formation of acid-hydrolyzable conjugate in man. J Clin Invest 1966; 45:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/71\">",
"      TAIT JF, LITTLE B, TAIT SA, et al. SPLANCHNIC EXTRACTION AND CLEARANCE OF ALDOSTERONE IN SUBJECTS WITH MINIMAL AND MARKED CARDIAC DYSFUNCTION. J Clin Endocrinol Metab 1965; 25:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/72\">",
"      Knights KM, Bowalgaha K, Miners JO. Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. Drug Metab Dispos 2010; 38:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9240/abstract/73\">",
"      BAULIEU EE, CORPECHOT C, DRAY F, et al. AN ADRENAL-SECRETED \"ANDROGEN\": DEHYDROISOANDROSTERONE SULFATE. ITS METABOLISM AND A TENTATIVE GENERALIZATION ON THE METABOLISM OF OTHER STEROID CONJUGATES IN MAN. Recent Prog Horm Res 1965; 21:411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 135 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9240=[""].join("\n");
var outline_f9_1_9240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H239061040\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLUCOCORTICOID METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818315\">",
"      Hepatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Oxidation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hydroxylation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Conjugation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alterations in hepatic metabolism of cortisol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Age and disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Obesity and Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Extrahepatic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ALDOSTERONE METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Conjugation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alterations in aldosterone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADRENAL ANDROGEN METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239061040\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/135|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/46/3818\" title=\"figure 1\">",
"      Major pathways of cortisol metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=related_link\">",
"      Measurement of adrenal androgens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_1_9241="Zoledronic acid: Drug information";
var content_f9_1_9241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zoledronic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/4/8262?source=see_link\">",
"    see \"Zoledronic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F10911784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reclast&reg;;",
"     </li>",
"     <li>",
"      Zometa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aclasta&reg;;",
"     </li>",
"     <li>",
"      Zometa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F236015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Acetaminophen administration after the infusion may reduce symptoms of acute-phase reactions. Patients treated for multiple myeloma, osteoporosis, and Paget's disease should receive a daily calcium supplement and multivitamin containing vitamin D (if dietary intake is inadequate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypercalcemia of malignancy (albumin-corrected serum calcium &ge;12 mg/dL) (Zometa&reg;):",
"     </b>",
"     I.V.: 4 mg (maximum) given as a single dose. Wait at least 7 days before considering retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma or metastatic bone lesions from solid tumors (Zometa&reg;):",
"     </b>",
"     I.V.: 4 mg every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis, glucocorticoid-induced, treatment and prevention (Reclast&reg;, Aclasta&reg; [Canadian availability]):",
"     </b>",
"     I.V.: 5 mg once a year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis, prevention:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reclast&reg;: 5 mg once every 2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclasta&reg; (Canadian availability): 5 mg as a single (one-time) dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis, treatment (Reclast&reg;, Aclasta&reg; [Canadian availability]):",
"     </b>",
"     I.V.: 5 mg once a year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paget's disease:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reclast&reg;: 5 mg as a single dose.",
"     <b>",
"      Note:",
"     </b>",
"     Data concerning retreatment is not available; retreatment may be considered for relapse (increase in alkaline phosphatase) if appropriate, for inadequate response, or in patients who are symptomatic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aclasta&reg; (Canadian availability): 5 mg as a single (one-time) dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of aromatase inhibitor-induced bone loss in breast cancer (unlabeled use):",
"     </b>",
"     I.V.: 4 mg every 6 months for 5 years (Brufsky, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of androgen deprivation-induced bone loss in nonmetastatic prostate cancer (unlabeled use):",
"     </b>",
"     I.V.: 4 mg every 3 months for 1 year (Smith, 2003) or 4 mg every 12 months (Michaelson, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Acetaminophen administration after infusion may reduce symptoms of acute-phase reactions. Patients treated for multiple myeloma, osteoporosis, and Paget's disease should receive a daily calcium supplement with vitamin D.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F235974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Calculate the creatinine clearance using the Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Nononcology uses:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;35 mL/minute: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;35 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Oncology uses:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Multiple myeloma and bone metastases:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: 4 mg (no dosage adjustment necessary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-60 mL/minute: Reduce dose to 3.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-49 mL/minute: Reduce dose to 3.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-39 mL/minute: Reduce dose to 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hypercalcemia of malignancy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe impairment (serum creatinine &gt;4.5 mg/dL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     U.S. labeling: Evaluate risk versus benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Canadian labeling: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for renal toxicity (during treatment):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypercalcemia of malignancy: Evidence of renal deterioration: Evaluate risk versus benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple myeloma and bone metastases: Evidence of renal deterioration: Withhold dose until renal function returns to within 10% of baseline; renal deterioration defined as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal baseline creatinine: Increase of 0.5 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Abnormal baseline creatinine: Increase of 1 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reinitiate therapy at the same dose administered prior to treatment interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple myeloma: Albuminuria &gt;500 mg/24 hours (unexplained): Withhold dose until return to baseline, then re-evaluate every 3-4 weeks; consider reinitiating with a longer infusion time of at least 30 minutes (Kyle, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F235975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reclast&reg;: 5 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zometa&reg;: 4 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 4 mg/5 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zometa&reg;: 4 mg/5 mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infusion, solution [premixed]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aclasta&reg;: 5 mg (100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, solution",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11441699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Reclast&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241522.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241522.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F235948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Infuse over at least 15 minutes. Flush I.V. line with 10 mL NS flush following infusion. Infuse in a line separate from other medications. Patients should be appropriately hydrated prior to treatment. Acetaminophen after administration may reduce the incidence of acute reaction (eg, arthralgia, fever, flu-like symptoms, myalgia).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F236023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with calcium or other divalent cation-containing solutions (eg, LR).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Oncology-related uses:",
"     </i>",
"     Treatment of hypercalcemia of malignancy (albumin-corrected serum calcium &gt;12 mg/dL); treatment of multiple myeloma; treatment of bone metastases of solid tumors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Nononcology uses:",
"     </i>",
"     Treatment of Paget&rsquo;s disease of bone; treatment of osteoporosis in postmenopausal women (to reduce the incidence of fractures or to reduce the incidence of new clinical fractures in patients with low-trauma hip fracture); prevention of osteoporosis in postmenopausal women, treatment of osteoporosis in men (to increase bone mass); treatment and prevention of glucocorticoid-induced osteoporosis (in patients initiating or continuing prednisone &ge;7.5 mg/day [or equivalent] and expected to remain on glucocorticoids for at least 12 months)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F236011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of bone loss associated with aromatase inhibitor therapy in postmenopausal women with breast cancer; prevention of bone loss associated with androgen deprivation therapy in prostate cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6136763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zometa&reg; may be confused with Jevtana&reg;, Xtandi&reg;, Xgeva&reg;, Zofran&reg;, Zoladex&reg;, Zytiga&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: Reclast&reg; and Aclasta&reg; contain zoledronic acid, which is the same ingredient contained in Zometa&reg;; patients receiving Zometa&reg; should not be treated with Reclast&reg; or Aclasta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F236013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     An acute reaction (eg, arthralgia, fever, flu-like symptoms, myalgia) may occur within the first 3 days following infusion in up to 44% of patients; usually resolves within 3-4 days of onset, although may take up to 14 days to resolve. The incidence may be decreased with acetaminophen (prior to infusion and for 72 hours postinfusion).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oncology indications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Leg edema (5% to 21%), hypotension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (39%), fever (32% to 44%), headache (5% to 19%), dizziness (18%), insomnia (15% to 16%), anxiety (11% to 14%), depression (14%), agitation (13%), confusion (7% to 13%), hypoesthesia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (12%), dermatitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (5% to 14%), hypophosphatemia (12% to 13%), hypokalemia (12%), hypomagnesemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (29% to 46%), vomiting (14% to 32%), constipation (27% to 31%), diarrhea (17% to 24%), anorexia (9% to 22%), abdominal pain (14% to 16%), weight loss (16%), appetite decreased (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (22% to 33%), neutropenia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (55%), weakness (5% to 24%), myalgia (23%), arthralgia (5% to 21%), back pain (15%), paresthesia (15%), limb pain (14%), skeletal pain (12%), rigors (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal deterioration (8% to 17%; up to 40% in patients with abnormal baseline creatinine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (22% to 27%), cough (12% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Cancer progression (16%), moniliasis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (5% to 10%; grades 3/4: &le;1%), hypermagnesemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (10%), dysphagia (5% to 10%), mucositis (5% to 10%), stomatitis (8%), sore throat (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Granulocytopenia (5% to 10%), pancytopenia (5% to 10%), thrombocytopenia (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (grades 3/4: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pleural effusion, upper respiratory tract infection (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (nonspecific; 5% to 10%), metastases (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Nononcology indications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (2% to 24%), fever (9% to 22%), headache (4% to 20%), chills (2% to 18%), fatigue (2% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (&le;3%; Paget&rsquo;s disease 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (9% to 27%), myalgia (5% to 23%), back pain (4% to 18%), limb pain (3% to 16%), musculoskeletal pain (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Acute phase reaction (4% to 25%), flu-like syndrome (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to 8%), peripheral edema (3% to 6%), atrial fibrillation (1% to 3%), palpitation (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 9%), malaise (1% to 7%), hypoesthesia (&le;6%), lethargy (3% to 5%), vertigo (1% to 4%), hyperthermia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 3%), hyperhidrosis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (1% to 9%), diarrhea (5% to 8%), vomiting (2% to 8%), constipation (6% to 7%), dyspepsia (2% to 7%), abdominal discomfort/distension (1% to 2%), anorexia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (3% to 9%), arthritis (2% to 9%), rigors (8%), shoulder pain (&le;7%), neck pain (1% to 7%), weakness (2% to 6%), muscle spasm (2% to 6%), stiffness (1% to 5%), jaw pain (2% to 4%), joint swelling (&le;3%), paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye pain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: C-reactive protein increased (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      All indications:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure (requiring hospitalization/dialysis), anaphylactic reaction/shock, angioedema, bradycardia, conjunctivitis, episcleritis, femur fracture (diaphyseal or subtrochanteric), hematuria, hyperesthesia, hyperkalemia, hypernatremia, hyperparathyroidism, hypersensitivity, hypertension, injection site reaction (eg, itching, pain, redness), interstitial lung disease, iridocyclitis, iritis, joint and/or muscle pain (sometimes severe and/or incapacitating), orbital inflammation, osteonecrosis (primarily of the jaws), scleritis, taste perversion, toxic acute renal tubular necrosis, uveitis, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F235951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     All  indications: Hypersensitivity to zoledronic acid or any component of the formulatio",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nononcology uses: Additional contraindications: Hypocalcemia; use in patients with creatinine clearance (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ) &lt;35 mL/minute and use in patients with evidence of acute renal impairment due to an increased risk of renal failure",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     All indications: Hypersensitivity to zoledronic acid or other bisphosphonates, or any component of the formulation; pregnancy, breast-feeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nononcology uses: Additional contraindications: Uncorrected hypocalcemia at the time of infusion, use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;35 mL/minute and use in patients with evidence of acute renal impairment due to an increased risk of renal failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F235936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone fractures: Atypical, low energy, or low trauma femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; atypical femur fractures have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids. Patients receiving long-term (&gt;3-5 years) bisphosphonate therapy may be at an increased risk. Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture. Consider interrupting bisphosphonate therapy in patients who develop a femoral shaft fracture; assess for fracture in the contralateral limb.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:  Rare cases of urticaria and angioedema and very rare cases of anaphylactic reactions/shock have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Musculoskeletal pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): ONJ has been reported in patients receiving bisphosphonates. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery); a diagnosis of cancer, with concomitant chemotherapy, radiotherapy, or corticosteroids; poor oral hygiene, ill-fitting dentures; and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. A dental exam and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. The manufacturer&rsquo;s labeling states that there are no data to suggest whether discontinuing bisphosphonates in patients requiring invasive dental procedures  reduces the risk of ONJ. However, other experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). The benefit/risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure. Patients developing ONJ while on bisphosphonates should receive care by an oral surgeon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin-sensitive asthma: Use with caution in patients with aspirin-sensitive asthma; may cause bronchoconstriction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Has not been adequately studied in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: May cause a significant risk of hypocalcemia in patients with Paget&rsquo;s disease, in whom the pretreatment rate of bone turnover may be greatly elevated. Hypocalcemia must be corrected before initiation of therapy in patients with Paget's disease or osteoporosis. Ensure adequate calcium and vitamin D intake during therapy. Use caution in patients with disturbances of calcium and mineral metabolism (eg, hypoparathyroidism, thyroid/parathyroid surgery, malabsorption syndromes, excision of small intestine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple myeloma: According to the American Society of Clinical Oncology (ASCO) guidelines for bisphosphonates in multiple myeloma, treatment with zoledronic acid is not recommended for asymptomatic (smoldering) or indolent myeloma or with solitary plasmacytoma (Kyle, 2007). The National Comprehensive Cancer Network&reg; (NCCN) multiple myeloma guidelines (v.1.2013) also do not recommend the use of bisphosphonates in stage 1 or smoldering disease, unless part of a clinical trial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in mild-to-moderate renal impairment. Single and multiple infusions in patients with both normal and impaired renal function have been associated with renal deterioration, resulting in renal failure and dialysis (rare). Pre-existing renal compromise, severe dehydration, and concurrent use with diuretics or other nephrotoxic drugs may increase the risk for renal impairment. Adequate hydration is required during treatment (urine output ~2 L/day); avoid overhydration, especially in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Nononcology indications:",
"     </i>",
"     Use is contraindicated in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;35 mL/minute and in patients with evidence of acute renal impairment. Patients with underlying moderate-to-severe renal impairment, increased age, concurrent use of nephrotoxic or diuretic medications, or severe dehydration prior to or after zoledronic acid administration may have an increased risk of acute renal impairment or renal failure. Others with increased risk include patients with renal impairment or dehydration secondary to fever, sepsis, gastrointestinal losses, or diuretic use. If history or physical exam suggests dehydration, treatment should not be given until the patient is normovolemic.  Creatinine clearance (using actual body weight) should be calculated with the Cockcroft-Gault formula prior to each administration. Transient increases in serum creatinine may be more pronounced in patients with impaired renal function; monitoring creatinine clearance in at-risk patients taking other renally-eliminated drugs is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Oncology indications:",
"     </i>",
"     Dosage adjustment required with renal impairment. Use is not recommended in patients with severe renal impairment (serum creatinine &gt;3 mg/dL or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) and bone metastases (limited data); use in patients with hypercalcemia of malignancy and severe renal impairment (serum creatinine &gt;4.5 mg/dL for hypercalcemia of malignancy) should only be done if the benefits outweigh the risks. In cancer patients, renal toxicity has been reported with doses &gt;4 mg or infusions administered over 15 minutes. Risk factors for renal deterioration include pre-existing renal insufficiency and repeated doses and other bisphosphonates therapy. Dehydration and the use of other nephrotoxic drugs which may contribute to renal deterioration should be identified and managed. Diuretics should not be used before correcting hypovolemia. Assess renal function  prior to treatment and withhold for renal deterioration (increase in serum creatinine of 0.5 mg/dL [if baseline level normal] or increase of 1 mg/dL [if baseline level abnormal]); treatment should be withheld until renal function returns to within 10% of baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly due to the possibility for decreased renal function; monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not approved for use in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women of childbearing age: Advise women of childbearing age against becoming pregnant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Do not administer Zometa&reg; and Reclast&reg; to the same patient for different indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reclast&reg;: Re-evaluate the need for continued therapy for the treatment of osteoporosis periodically; the optimal duration of treatment has not yet been determined.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thalidomide: May enhance the adverse/toxic effect of Zoledronic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies resulted in embryotoxicity and losses. Zoledronic acid should not be used during pregnancy; may cause fetal harm if administered to a pregnant woman. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F235982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2998081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Because it binds to bone long term, zoledronic acid use is not recommended in nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F235955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multiple myeloma or metastatic bone lesions from solid tumors: Take daily calcium supplement (500 mg) and daily multivitamin (with 400 units vitamin D).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Osteoporosis: Ensure adequate calcium and vitamin D supplementation; general requirements are calcium 1200 mg/day and vitamin D 800-1000 units/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paget&rsquo;s disease: Take elemental calcium 1500 mg/day (750 mg twice daily or 500 mg 3 times/day) and vitamin D 800 units/day, particularly during the first 2 weeks after administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F235953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Zoledronic Acid Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (5 mL): $956.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Zometa Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (5 mL): $1074.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Reclast Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/100 mL (100 mL): $1300.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zometa Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/100 mL (100 mL): $1074.73",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F235944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to initiation of therapy, dental exam and preventative dentistry for patients at risk for osteonecrosis, including all cancer patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nononcology uses: Serum creatinine prior to each dose, especially in patients with risk factors, calculate creatinine clearance before each treatment (consider interim monitoring in patients at risk for acute renal failure), evaluate fluid status and adequately hydrate patients prior to and following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Osteoporosis: Bone mineral density as measured by central dual-energy x-ray absorptiometry (DXA) of the hip or spine (prior to initiation of therapy and at least every 2 years; after 6-12 months of combined glucocorticoid and zoledronic acid treatment); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; phosphorus and magnesium; may consider monitoring biochemical markers of bone turnover",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Paget&rsquo;s disease: Alkaline phosphatase; pain; serum calcium and 25(OH)D; phosphorus and magnesium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oncology uses: Serum creatinine prior to each dose; serum electrolytes, phosphate, magnesium, and hemoglobin/hematocrit should be evaluated regularly. Monitor serum calcium to assess response and avoid overtreatment. In patients with multiple myeloma, monitor urine every 3-6 months for albuminuria.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F235956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aclasta (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Blaztere (IN);",
"     </li>",
"     <li>",
"      Bolenic (TW);",
"     </li>",
"     <li>",
"      Zinvel (TH);",
"     </li>",
"     <li>",
"      Zobonic (TW);",
"     </li>",
"     <li>",
"      Zomera (IL);",
"     </li>",
"     <li>",
"      Zometa (AR, AT, AU, BE, BG, BO, BR, CH, CL, CN, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, ID, IE, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PR, PT, PY, RU, SE, SG, SK, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F235935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; inhibits osteoclastic activity and skeletal calcium release induced by tumors. Decreases serum calcium and phosphorus, and increases their elimination. In osteoporosis, zoledronic acid inhibits osteoclast-mediated resorption, therefore reducing bone turnover.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F235950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Binds to bone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 23% to 53%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Triphasic; Terminal: 146 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (39% &plusmn; 16% as unchanged drug) within 24 hours; feces (&lt;3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       JADA",
"      </i>",
"      , 2006, 137(8):1144-50. Available at file://jada.ada.org/cgi/content/full/137/8/1144",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/16873332/pubmed\" id=\"16873332\" target=\"_blank\">",
"        16873332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, &ldquo;Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berenson JR, Boccia R, Lopez T, et al, &ldquo;Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial),",
"      <i>",
"       J Support Oncol",
"      </i>",
"      , 2011, 9(1):32-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21465735/pubmed\" id=\"21465735\" target=\"_blank\">",
"        21465735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Black DM, Delmas PD, Eastell R, et al, &ldquo;Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2007, 356(18):1809-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/17476007/pubmed\" id=\"17476007\" target=\"_blank\">",
"        17476007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Body JJ, &ldquo;Clinical Research Update: Zoledronate,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1997, 80(Suppl):1699-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/9362440/pubmed\" id=\"9362440\" target=\"_blank\">",
"        9362440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boonen S, Sellmeyer DE, Lippuner K, et al, &ldquo;Renal Safety of Annual Zoledronic Acid Infusions in Osteoporotic Postmenopausal Women,&rdquo;",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 2008, 74(5):641-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/18509324/pubmed\" id=\"18509324\" target=\"_blank\">",
"        18509324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brufsky A, Harker WG, Beck JT, et al, &ldquo;Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      2007, 25(7):829-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/17159193/pubmed\" id=\"17159193\" target=\"_blank\">",
"        17159193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brufsky AM, Harker WG, Beck JT, et al, &ldquo;Final 5-year results of Z-FAST Trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2012, 118(5):1192-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21987386/pubmed\" id=\"21987386\" target=\"_blank\">",
"        21987386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleman RE and Seaman JJ, &ldquo;The Role of Zoledronic Acid in Cancer: Clinical Studies in the Treatment and Prevention of Bone Metastases,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2001, 28(2 Suppl 6):11-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/11346860/pubmed\" id=\"11346860\" target=\"_blank\">",
"        11346860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coleman RE, Marshall H, Cameron D, et al, &ldquo;Breast-Cancer Adjuvant Therapy With Zoledronic Acid,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(15):1396-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21995387/pubmed\" id=\"21995387\" target=\"_blank\">",
"        21995387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durie BG, Katz M, and Crowley J, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(1):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/16000365/pubmed\" id=\"16000365\" target=\"_blank\">",
"        16000365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eidtmann H, de Boer R, Bundred N, et al, &ldquo;Efficacy of Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: 36-Month Results of the ZO-FAST Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(11):2188-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/20444845/pubmed\" id=\"20444845\" target=\"_blank\">",
"        20444845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Francini F, Pascucci A, Francini E, et al, &ldquo;Osteonecrosis of the Jaw in Patients With Cancer Who Received Zoledronic Acid and Bevacizumab,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2011, 142(5):506-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21531932/pubmed\" id=\"21531932\" target=\"_blank\">",
"        21531932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gnant M, Mlineritsch B, Schippinger W, et al, &ldquo;Endocrine Therapy Plus Zoledronic Acid in Premenopausal Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(7):679-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/19213681/pubmed\" id=\"19213681\" target=\"_blank\">",
"        19213681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grbic JT, Black DM, Lyles KW, et al, &ldquo;The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid: Data From the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Clinical Trials Program,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(11):1365-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21037195/pubmed\" id=\"21037195\" target=\"_blank\">",
"        21037195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hadji P, Aapro MS, Body JJ, et al, &ldquo;Management of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Breast Cancer: Practical Guidance for Prevention and Treatment,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2011, 22(12):2546-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21415233/pubmed\" id=\"21415233\" target=\"_blank\">",
"        21415233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershman DL, McMahon DJ, Crew KD, et al, &ldquo;Prevention of Bone Loss By Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist Up to One Year Following Discontinuing Treatment,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(2):559-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/20022990/pubmed\" id=\"20022990\" target=\"_blank\">",
"        20022990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillner BE, Ingle JN, Chlebowski RT, et al, &ldquo;American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(21):4042-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/12963702/pubmed\" id=\"12963702\" target=\"_blank\">",
"        12963702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kyle RA, Yee GC, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(17):2464-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/17515569/pubmed\" id=\"17515569\" target=\"_blank\">",
"        17515569",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyles KW, Colon-Emeric CS, Magaziner JS, et al, &ldquo;Zoledronic Acid and Clinical Fractures and Mortality After Hip Fracture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 357(18):1799-809.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/17878149/pubmed\" id=\"17878149\" target=\"_blank\">",
"        17878149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maerevoet M, Martin C, and Duck L, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(1):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/16003838/pubmed\" id=\"16003838\" target=\"_blank\">",
"        16003838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo;",
"      <i>",
"       Menopause",
"      </i>",
"      , 2010, 17(1):25-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/20061894/pubmed\" id=\"20061894\" target=\"_blank\">",
"        20061894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McClung M, Miller P, Recknor C, et al, &ldquo;Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(5):999-1007.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/20168099/pubmed\" id=\"20168099\" target=\"_blank\">",
"        20168099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMahon RE, Bouquot JE, Glueck CJ, et al, &ldquo;Osteonecrosis: A Multifactorial Etiology,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2004, 62(7):904-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/15244000/pubmed\" id=\"15244000\" target=\"_blank\">",
"        15244000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michaelson MD, Kaufman DS, Lee H, et al, &ldquo;Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men With Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(9):1038-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/17369566/pubmed\" id=\"17369566\" target=\"_blank\">",
"        17369566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan GJ, Davies FE, Gregory WM, et al, &ldquo;Effects of Induction and Maintenance Plus Long-Term Bisphosphonates on Bone Disease in Patients With Multiple Myeloma: The Medical Research Council Myeloma IX Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(23):5374-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/22498739/pubmed\" id=\"22498739\" target=\"_blank\">",
"        22498739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Multiple Myeloma,&rdquo; Version 1.2013. Available at  file://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo;",
"      <i>",
"       Bone",
"      </i>",
"      , 2008, 43(5):819-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/18672105/pubmed\" id=\"18672105\" target=\"_blank\">",
"        18672105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reid DM, Devogelaer JP, Saag K, et al, &ldquo;Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (HORIZON): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9671):1253-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/19362675/pubmed\" id=\"19362675\" target=\"_blank\">",
"        19362675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reid IR, Miller P, Lyles K, et al, &ldquo;Comparison of a Single Infusion of Zoledronic Acid With Risedronate for Paget's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(9):898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/16135834/pubmed\" id=\"16135834\" target=\"_blank\">",
"        16135834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Renouf D, Velazquez-Martin JP, Simpson R, et al, &ldquo;Ocular Toxicity of Targeted Therapies,&rdquo;",
"      <i>",
"       J Clinl Oncol",
"      </i>",
"      , 2012, 30(26):3277-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/22649132/pubmed\" id=\"22649132\" target=\"_blank\">",
"        22649132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruggiero SL, Dodson TB, Assael LA, et al, &ldquo;American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws-2009 Update,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):2-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/19371809/pubmed\" id=\"19371809\" target=\"_blank\">",
"        19371809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sayin M and Yazici G, &ldquo;Hyperparathyroidism Secondary to Zoledronic Acid Infusion: Case Report,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2009, 17(5):469-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/19205753/pubmed\" id=\"19205753\" target=\"_blank\">",
"        19205753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(13):1480-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/20924014/pubmed\" id=\"20924014\" target=\"_blank\">",
"        20924014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(11):2267-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/20842676/pubmed\" id=\"20842676\" target=\"_blank\">",
"        20842676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith MR, Eastham J, Gleason DM, et al, &ldquo;Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2003, 169(6):2008-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/12771706/pubmed\" id=\"12771706\" target=\"_blank\">",
"        12771706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tarassoff P and Csermak K, &ldquo;Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2003, 61(10):1238-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/14586868/pubmed\" id=\"14586868\" target=\"_blank\">",
"        14586868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(6):593-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/16899779/pubmed\" id=\"16899779\" target=\"_blank\">",
"        16899779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Poznak CH, Temin S, Yee GC, et al, &ldquo;American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(9):1221-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/1/9241/abstract-text/21343561/pubmed\" id=\"21343561\" target=\"_blank\">",
"        21343561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9902 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9241=[""].join("\n");
var outline_f9_1_9241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10911784\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235968\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235969\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236015\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235972\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235973\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235974\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235975\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235946\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076370\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235932\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441699\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235948\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236023\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235947\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236011\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6136763\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236013\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235951\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235936\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300240\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235940\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235942\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235954\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235982\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2998081\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235955\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235953\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235944\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235956\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235935\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235950\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/4/8262?source=related_link\">",
"      Zoledronic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_1_9242="Hemodialysis for children with chronic kidney disease";
var content_f9_1_9242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemodialysis for children with chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9242/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9242/contributors\">",
"     Lesley Rees, MD, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9242/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/1/9242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/1/9242/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/1/9242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H118550430\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the principles of hemodialysis (HD) are similar for adults and children, there are technical aspects of the procedure and complications, which are unique to the pediatric population. It is crucial that these differences are recognized and addressed in order to effectively and safely perform pediatric HD, thereby reducing complications in children who are facing a lifetime of renal replacement therapy (RRT).",
"   </p>",
"   <p>",
"    Hemodialysis in children with chronic kidney disease (CKD), including discussions on types of vascular access and dialyzers, dialysis prescription, and complications, will be reviewed here. Overviews on the management of pediatric CKD and RRT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118551084\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of pediatric hemodialysis (HD) are the same as those in adults undergoing HD: effective and safe clearance of uremic toxins, and removal of excess fluid. These principles and a general description of HD apparatus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=see_link\">",
"     \"Overview of the hemodialysis apparatus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following aspects of HD, which may differ in adults and children, need to be considered and addressed in order to effectively and safely perform pediatric HD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vascular access",
"     </li>",
"     <li>",
"      Extracorporeal circuit (eg, size and volume of tubing and dialyzer)",
"     </li>",
"     <li>",
"      Choice of dialyzer and machines",
"     </li>",
"     <li>",
"      Dialysis prescription particularly blood flows",
"     </li>",
"     <li>",
"      Complications and outcome measures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60775273\">",
"    <span class=\"h2\">",
"     Multidisciplinary team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of the child on HD is not possible without input and care from a multidisciplinary team.",
"   </p>",
"   <p>",
"    Key members of the team include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrologists, nurses, and surgeons with expertise in caring for children receiving HD",
"     </li>",
"     <li>",
"      Dieticians who understand the implications of CKD and HD on nutrition and growth in affected children",
"     </li>",
"     <li>",
"      Radiologists with expertise in pediatric vascular access imaging and intervention",
"     </li>",
"     <li>",
"      Play therapists who can prepare the child for dialysis and in particular, provide distraction therapy when acquiring vascular access",
"     </li>",
"     <li>",
"      Social workers and psychologists to support both the patient and family",
"     </li>",
"     <li>",
"      School",
"      <span class=\"nowrap\">",
"       teachers/tutors,",
"      </span>",
"      particularly for patients whose schooling is interrupted by center-based dialysis sessions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760051\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good vascular access is one of the most important factors for successful hemodialysis (HD). The three forms of vascular access in children are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Native arteriovenous (AV) fistulas",
"     </li>",
"     <li>",
"      Subcutaneously tunneled central venous catheters (CVCs)",
"     </li>",
"     <li>",
"      Synthetic AV grafts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most would agree that the best form of access is an arteriovenous (AV) fistula because tunneled CVCs frequently malfunction, become infected, and often need replacement, thus damaging central veins and therefore precluding future fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, a tunneled CVC is typically used in children when it is likely to be required for a short duration of time (eg, the child awaiting living related renal transplantation). Because AV fistulas require time to mature (ie, several weeks to months), early planning is required [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/4\">",
"     4",
"    </a>",
"    ]. Grafts are usually only used whenever other access(es) has failed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link&amp;anchor=H9#H9\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\", section on 'Time to use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In spite of its limitations, HD in the majority of children is initiated through a CVC as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the North American Pediatric Renal Trials and Collaborative studies (NAPRTCS) from 2008 included 3,047 HD accesses in children with end stage renal disease (ESRD) and showed HD was initiated 78, 12, and 7 percent through external percutaneous catheters, AV fistulas, and AV grafts, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the United States Renal Data system (USRDS) showed that about 40 percent of children who were receiving chronic HD continued to use catheters for vascular access [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) from 2008 demonstrated that catheters were used exclusively as vascular access for children below 10 years of age for both first HD treatment and continued HD treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/7\">",
"       7",
"      </a>",
"      ]. For older children, catheters were used in about 90 percent of patients at the start of HD treatment in both Australia and New Zealand and then fell to 54 percent in Australia and 29 percent in New Zealand with increasing use of AV fistulas in both countries.",
"     </li>",
"     <li>",
"      In a survey of participating centers in the European Pediatric Dialysis Working Group, CVC was the access used in 60 percent of 111 patients undergoing chronic hemodialysis, AV fistula in 38 percent of patients, and AV graft in 2 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for the high prevalence of CVCs include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is technically more difficult to create AV fistulas, especially in small children, and their needling may be challenging for the child and staff in young children or children with behavioral problems. A center in France, however, has successfully used microsurgery to create fistulas even in infants but this is not universally available [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/11\">",
"       11",
"      </a>",
"      ]. Some centers use AV grafts in younger children, but complications, such as stenosis, thrombosis, and infection, are more common leading to a shorter vascular access survival time [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anticipation of a short and temporary dialysis course prior to renal transplantation.",
"     </li>",
"     <li>",
"      Avoidance of needling accesses in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have shown that the use of AV fistulas is associated with more effective dialysis with fewer complications (eg, infection, time spent in hospital) than percutaneous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. Based upon these observations, the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) encourages the use of AV fistulas in children large enough for placement of an AV fistulas receiving hemodialysis who are not likely to receive a transplant within 12 months. (See",
"    <a class=\"local\" href=\"#H349365238\">",
"     'AV fistula'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118551405\">",
"    <span class=\"h2\">",
"     Tunneled catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children undergoing chronic HD, the cuffed CVCs commonly used are dual lumen catheters composed of silicone or polyurethane composites. However, in small children, the distance between the arterial and venous ends of the catheter in double lumen catheters may be too far apart to allow successful positioning of both lumens. Split catheters (the two catheters are of equal length and joined proximally but separated distally) may be of benefit in this situation (",
"    <a class=\"graphic graphic_picture graphicRef66261 \" href=\"UTD.htm?20/43/21183\">",
"     picture 1",
"    </a>",
"    ) or the use of two separate single lumen catheter systems that can be inserted in the same vein with different exit sites or in different veins altogether.",
"   </p>",
"   <p>",
"    In very small children, single lumen access may be more appropriate, as a larger catheter can be inserted, remembering that flow is proportional to the fourth power of the radius. In order to obtain two directional blood flows with a single lumen line, the dialysis circuit has to be modified. This can be achieved by the double-pump method, using two blood pumps, which pump alternately, or by using a single pump which pumps intermittently, using gravity to let blood flow back in to the child. Both methods require an expansion chamber in the circuit to allow for the pressure changes. This results in an increased volume of blood in the circuit, which may require priming the external circuit with donor blood. There will be a larger degree of recirculation with this system. (See",
"    <a class=\"local\" href=\"#H241185639\">",
"     'Extracorporeal circuit'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Catheter sizes range from 6.5 to 14 FG and are chosen according to the size of the vessels of the child. These catheters are available in different lengths based on the gauge (12 or 18 cm for smaller gauge catheters, and 12 to 40 cm for larger gauge catheters) (",
"    <a class=\"graphic graphic_table graphicRef57580 \" href=\"UTD.htm?35/36/36427\">",
"     table 1",
"    </a>",
"    ). Increasing the gauge of the vascular access will allow for higher blood flow rates. However, too large a catheter can potentially lead to obstruction of vessels, resulting in reduced venous return and therefore poor flow through the dialysis circuit.",
"   </p>",
"   <p>",
"    Catheters are most commonly placed in the internal jugular vein and tunneled superficially to exit on the upper anterior chest. The catheter tip should be located at the junction of the superior vena cava (SVC) and right atrium, or in the right atrium to provide adequate dialysis. Catheters located in the SVC may have inadequate blood flow because the entry and exit sites often seal off as they abut up against the vessel wall. Positioning of a catheter in a small child can be difficult due to size and is best undertaken using ultrasound guidance by a skilled operator. In neonates, the femoral vein may be used as a temporary access, but this is not ideal as damage to the inferior venal cava may make future transplantation difficult. The subclavian vein should be avoided if at all possible, as stenosis may prevent successful fistula formation in the future.",
"   </p>",
"   <p>",
"    The most frequent complication of tunneled catheters is malpositioning and therefore malfunction, which is commoner the smaller the child.",
"   </p>",
"   <p>",
"    Infection is also a frequent complication and is linked to malpositioning because repeated disconnection and flushing of the line increases the chances of introduction of organisms. Infection then causes vessel damage and stenosis, furthering the problem with poor flows and impacting on future fistula creation. Strict catheter management decreases the risk of infection. In a study from a tertiary pediatric center in Israel with an infection rate of 0.05 per 100 treatment days, management includes rinsing the catheter, soaking the CVC head, handwashing (patient, nurse, and parent) with solutions that contain varying concentrations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    , and the use of masks and sterile gloves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349365238\">",
"    <span class=\"h2\">",
"     AV fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV fistulas are typically constructed with an end-to-side, vein-to-artery anastomosis. The most commonly used fistulas are created by anastomosing the radial artery and cephalic vein (radiocephalic or wrist fistula) or by anastomosing the brachial artery and cephalic vein (brachiocephalic or upper arm fistula) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/4\">",
"     4",
"    </a>",
"    ]. The former can be difficult in small children due to vessel size. The lifetime of a fistula is superior to a tunneled line; over two thirds are still functioning after five years, whereas reports of the survival of tunneled lines vary from 30 to 85 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complication rates appear to be lower with AV fistulas (AVF):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a long-term follow-up study of children with an AVF or CVC for more than a year, access survival rates (including both primary and secondary access failure) were significantly higher for AVF compared with CVC. Primary access failure was 1 per 78.8 patient-months for AVF and was 1 per 15.5 patient-months for CVCs. Failures thereafter for AVF and CVCs were 1 per 131.3 and 1 per 18.5 patients months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/3\">",
"       3",
"      </a>",
"      ].The risk of infection was also lower with AV fistulas than CVCs ( 0.25 versus 3.2 per 100 patient-months). In addition, the annualized hospitalization rate for access malfunction was lower in patients with AVFs compared with those with CVCs (0.44 versus 3.1 percent). In the two-center study, the incidence of revisions requiring hospitalization was 0.2 and 2.7 per 100 treatments for fistulas compared with CVCs, respectively.",
"     </li>",
"     <li>",
"      In a review from two large centers over a one-year period, the infection rate was 0.2 per 100 treatments in children with AVFs compared with 3.7 per 100 treatments in those with CVCs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/12\">",
"       12",
"      </a>",
"      ]. The incidence of revisions requiring hospitalization was 0.2 and 2.7 per 100 treatments for fistulas compared with CVCs, respectively.",
"     </li>",
"     <li>",
"      The previously mentioned Israeli study also reported a lower rate of infection of 0.05 per 100 treatments in children including infants who received HD through a CVC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/2\">",
"       2",
"      </a>",
"      ]. In this study, the median catheter survival time was 310 days. The authors attributed the lower infection rate to adherence to a strict catheter management protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, clinical experience, and patient preferences, we suggest initiating HD through an AV fistula in pediatric patients in whom there is time for it to mature, who are large enough that this is technically feasible, are not likely to receive a transplant within six months, and who can be prepared to tolerate needling of the AV fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167575172\">",
"    <span class=\"h1\">",
"     HD EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment for hemodialysis (HD) includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tubing",
"     </li>",
"     <li>",
"      Dialyzer",
"     </li>",
"     <li>",
"      Dialysis machine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241185639\">",
"    <span class=\"h2\">",
"     Extracorporeal circuit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extracorporeal circuit is composed of the arterial (inflow) and venous (outflow) lines, and the dialyzer. The volume of this circuit is restricted by the upper safe limit for extracorporeal blood volume that is dependent on the total blood volume of the patient. A child can tolerate 8 percent (up to a maximum of 10 percent) of their total blood volume (80",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    estimated optimum weight) in the extracorporeal circuit. The volume of the lines and dialyzer must not exceed this volume. As an example, the upper safe limit for a child who weighs 10 kg (total blood volume of 800 mL) would be 64 to 80 mL.",
"   </p>",
"   <p>",
"    A variety of HD tubing with specific volumes is commercially available. Tubing should be matched to the size of the patient based on the upper safe limit of extracorporeal blood volume (",
"    <a class=\"graphic graphic_table graphicRef77610 \" href=\"UTD.htm?18/34/18987\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In some infants, however, even the smallest circuit may exceed the safe extracorporeal volume. If this is the case, the circuit must be primed with donated blood. This carries the risk of HLA sensitization, with its consequent difficulties for transplantation, and is another reason for choosing peritoneal dialysis (PD) in infants. The blood in the lines (if they have been primed with blood) is not washed back into the infant at the completion of HD unless a transfusion is required, because this would be the equivalent of giving blood equal to the volume of the lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760067\">",
"    <span class=\"h2\">",
"     Dialyzer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of dialyzer generally used in children is a hollow fiber design that minimizes blood volume, and provides reliable and predictable solute clearance and ultrafiltration coefficients. A wide variety of hollow fiber dialyzers with different blood volumes is commercially available, and the dialyzer is selected on the basis of the size of the child (ie, surface area of the child) and the type of hemodialysis (eg, standard or hemodiafiltration [HDF]). The size of the dialyzer is calculated by its surface area. The surface area should be as large as possible to optimize clearances but should not exceed that of the child's. At present, dialyzer surface areas range from 0.25 m",
"    <sup>",
"     2",
"    </sup>",
"    up to 1.7 m",
"    <sup>",
"     2",
"    </sup>",
"    and above.",
"   </p>",
"   <p>",
"    A discussion of the different types of dialyzers is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the hemodialysis apparatus\", section on 'Dialyzer types'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760075\">",
"    <span class=\"h2\">",
"     HD machine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of the HD machine include a blood pump to move blood between patient and the dialyzer, a delivery system to transport dialysis solution, and monitoring devices. Pressure monitors located proximal to the blood pump and distal to the dialyzer guard against excessive suction of blood from and excessive resistance to blood return to the patient's vascular access site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the hemodialysis apparatus\", section on 'Dialysis machines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, HD machines used in children, especially small children and infants, must have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A volumetric fluid removal system, in which the inflow and outflow volumes from the dialyzer are measured so that ultrafiltrate (UF) volume (volume removed during the dialysis treatment) is measured directly and very small amounts of fluid can be removed.",
"     </li>",
"     <li>",
"      Capability of low blood flow speeds. (See",
"      <a class=\"local\" href=\"#H6761650\">",
"       'Blood flows'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ability to use lines of varying blood volumes. (See",
"      <a class=\"local\" href=\"#H241185639\">",
"       'Extracorporeal circuit'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167575180\">",
"    <span class=\"h1\">",
"     DIALYSIS PRESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For each patient, a dialysis prescription is developed so that there is adequate solute clearance and removal of excess fluid. The components of the prescription include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Selection of the dialyzer",
"     </li>",
"     <li>",
"      Hemodialysis or hemodiafiltration (HDF)",
"     </li>",
"     <li>",
"      Selection of the tubing (",
"      <a class=\"graphic graphic_table graphicRef77610 \" href=\"UTD.htm?18/34/18987\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blood flow rate",
"     </li>",
"     <li>",
"      Length and frequency of dialysis sessions",
"     </li>",
"     <li>",
"      Determination of fluid removal amount",
"     </li>",
"     <li>",
"      Heparinization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241185624\">",
"    <span class=\"h2\">",
"     Dialyzer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each center typically picks one type of commercially available dialyzer for their unit, although more than one type may be necessary depending on the sizes of dialyzer required and whether the child is treated with conventional hemodialysis (HD) or hemodiafiltration (HDF). Solute clearance is increased with HDF, which raises the convective clearance rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30330?source=see_link&amp;anchor=H7#H7\">",
"     \"Alternative renal replacement therapies in end-stage renal disease\", section on 'Hemofiltration and hemodiafiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each type of dialyzer has an ultrafiltration coefficient (KUf), which describes its ability to remove water. KUf depends on the surface area of the dialyzer and the membrane characteristics. Dialyzers with KUfs of less than 10 are referred to as low-flux, and those with a rate of 15 to 60",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    per mmHg are called high flux.",
"   </p>",
"   <p>",
"    High flux dialyzers offer improved permeability for middle and larger molecules. They are particularly needed for HDF. However, even with HD, there is some back diffusion, leading to unquantified convective clearance. These types of filters, therefore, require the use of ultra pure water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6761650\">",
"    <span class=\"h2\">",
"     Blood flows",
"    </span>",
"    &nbsp;&mdash;&nbsp;The speed at which the blood is pumped out of the child and around the circuit is an important determinant of solute clearance. Although higher blood flows increase solute clearance by optimizing diffusion and convection, excessive blood flows can compromise cardiovascular stability. Blood flow speed has to be adjusted to the size of the child and should not exceed their maximum extracorporeal volume in",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    (ie, up to body weight (kg) x 8",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    in order to safely maintain their cardiovascular status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760083\">",
"    <span class=\"h2\">",
"     Length of dialysis and frequency of sessions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional hemodialysis is generally performed three times a week with the duration of the session depending on the predetermined amount and rate of solute clearance and fluid removal. Individual sessions are rarely less than four hours.",
"   </p>",
"   <p>",
"    Solute clearance is greater with increasing dialysis time at a center or home. Better phosphate and blood pressure (BP) control have been reported with increasing both the length of HD sessions to six and eight hours, and frequency from three to six or seven times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. In addition, short, frequent HDF treatments of two to three hours duration with a frequency of five to seven times per week are associated with improved mineral (eg, phosphate and calcium) and BP control. The increased dialysis time has eliminated the need for antihypertensive medications and phosphate binders, and improved appetite, growth, and quality of life. With increased intensity of nutrition and hemodialysis (eg, hemodiafiltration six times per week or nocturnal hemodialysis), single-center studies have also reported that the growth rate of children on maintenance hemodialysis improved significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who benefit most from increased dialysis treatments are those likely to remain on HD long term, have chronic fluid overload, hyperphosphatemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor growth, or are infants, whose predominantly liquid diet requires removal of relatively large fluid volumes.",
"   </p>",
"   <p>",
"    Longer hours of HD at dialysis centers are limited by resources. Therefore, in many institutions, increasing dialysis frequency (ie, time) is reserved for infants, in whom fluid balance is difficult to control with conventional thrice weekly dialysis. The use of home HD is increasing with the development of simpler new dialysis machines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/14,20\">",
"     14,20",
"    </a>",
"    ] and is an option for children who have adequate housing and a family member who is able and accepts the responsibility of performing HD. Home HD has become an option for smaller children with the availability of circuits to dialyze children with weights from 25 kg. HDF is also beginning to be used more widely in pediatrics as filters and lines are becoming available for smaller children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760099\">",
"    <span class=\"h2\">",
"     Fluid removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of fluid removal per session is dependent on the difference between the predialytic weight and the optimal weight of the patient. Although the amount of fluid that a child will tolerate losing per hour varies, a generally safe starting point is about 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour. Removal of more than 5 percent of body weight in one session, or 0.2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute, is very likely to result in symptomatic hypovolemia. In children who weigh more than 40 kg, typically 600",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    can be removed without significant symptoms in patients who are consistently volume overloaded as they become tolerant of larger fluid shifts.",
"   </p>",
"   <p>",
"    In some patients, attainment of optimum weight with conventional HD performed three times a week can be challenging. This includes infants who are maintained on a liquid diet and children who have difficulty in complying with interdialytic fluid restriction. In these patients, high interdialytic weight gains due to excess fluid retention would require large UF volumes during each dialysis session that exceed the upper safe limit resulting in symptomatic hypovolemia. Such children need more frequent dialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6760083\">",
"     'Length of dialysis and frequency of sessions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H167575773\">",
"    <span class=\"h3\">",
"     Estimation of optimum weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of growth, estimation of optimum weight requires regular ongoing assessment. The frequency depends on the age of the patient: the young infant, who should gain 200 gm per week, clearly needs assessment every week, whereas an older child can be assessed every month.",
"   </p>",
"   <p>",
"    The aim is to end the session with the child at his or her",
"    <span class=\"nowrap\">",
"     target/optimum",
"    </span>",
"    weight, which is the weight below which the child will become symptomatically hypotensive. Target weight can only be determined by careful but persistent fluid removal to achieve a normal BP for age after dialysis. The child who is always hypertensive is likely to be above his or her target weight; antihypertensive medications are usually unnecessary when optimum weight is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695269\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    is the standard anticoagulant used during hemodialysis. It can be infused slowly and continuously throughout the session to prevent blood clotting within the circuit. It is administered at a rate of 5 to 50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour through the arterial side of the circuit. Some units use low molecular weight heparin, given as a bolus of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at the beginning of the dialysis session. Newer non-heparin anticoagulants are becoming available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760107\">",
"    <span class=\"h1\">",
"     MEASUREMENTS OF ADEQUACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic toxins can be divided into three groups: free and water soluble molecules, such as urea (removed during dialysis by diffusion and convection); middle molecules such as beta-2 microglobulin(removed principally by convection); and substances that are bound to circulating proteins. Some toxins are removed by binding to the HD membrane. The principal measures of HD adequacy use urea and, therefore, assess small solute clearance. Such measures of hemodialysis (HD) adequacy in children have not been defined, but consensus standards propose that they should be equal to or better than adult standards, which use one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialyzer clearance of urea",
"      <span class=\"nowrap\">",
"       (Kt/V),",
"      </span>",
"      where K is the clearance coefficient for urea of the dialyzer measured as",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      t is duration of the of dialysis treatment measured in minutes, and V is the distribution of urea in the body measure in mL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link&amp;anchor=H3#H3\">",
"       \"Kt/V and the adequacy of hemodialysis\", section on 'Definition and calculation of Kt/V'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urea reduction ratio (URR) defined by the following formula (1 - [postdialysis BUN &divide; predialysis BUN]). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link&amp;anchor=H6#H6\">",
"       \"Kt/V and the adequacy of hemodialysis\", section on 'Urea reduction ratio'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, it has been proposed that adequate HD be defined as &gt;1.2 for",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and &gt;65 percent for URR [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/10\">",
"     10",
"    </a>",
"    ]. One pediatric study found an improvement in hospitalization rates when using a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.4 as a standard for HD adequacy, but above this level there was no further improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/23\">",
"     23",
"    </a>",
"    ]. Other data suggest that daily or frequent short HD results in higher",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    which was associated with improvement in all aspects of patient well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. Measure of middle molecule clearance includes assessing the clearance of phosphate or beta-2 microglobulin.",
"   </p>",
"   <p>",
"    The protein catabolic rate (PCR), also called the protein equivalent of nitrogen appearance (PNA), is used to assess dietary protein intake in patients who are in a steady state, and varies directly with",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    It is used in conjunction with",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    to determine whether a desirably low predialysis BUN represents a well nourished patient who is adequately dialyzed, or a patient with a suboptimal protein intake and inadequate dialysis. It is more sensitive and specific than albumin as a marker of nutritional status because many processes unrelated to nutrition can affect albumin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children who receive chronic HD, PCR should be measured at least monthly with a goal of 1 to 1.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    along with an adequate",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    level to ensure adequate nutrition and dialysis clearance. Studies in adults have shown that adequate dialysis clearance and nutrition are associated with lower morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link&amp;anchor=H2#H2\">",
"     \"Kt/V and the adequacy of hemodialysis\", section on 'Background'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other objective assessments of dialysis adequacy are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of growth parameters, and comparison of height, weight, head circumference, and pubertal stage to age-adjusted normal growth standards.",
"     </li>",
"     <li>",
"      Control of anemia, acidosis, and biochemical parameters.",
"     </li>",
"     <li>",
"      Hospitalizations and school attendance.",
"     </li>",
"     <li>",
"      Optimal BP control is the most useful assessment of adequacy of ultrafiltration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760115\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of hemodialysis (HD) that occur in adults are also seen in children including malnutrition, abnormalities of mineral metabolism, and bone and cardiovascular disease. In addition, there are unique issues for the pediatric population, such as poor growth and neuropsychological impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760122\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is common in children receiving chronic HD, and is associated with an increased risk of poor growth and death.",
"   </p>",
"   <p>",
"    Several different observational studies have shown the association between poor nutrition (and poor growth) with increased mortality in children undergoing dialysis. The risk of death is reported to be:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      54 percent higher for each 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      fall in albumin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      57 percent reduced if the serum albumin &gt;4.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      14 percent increased with each decrease of one height standard deviation score (SDS) below normal at the start of dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Twofold higher in patients with a height SDS of &lt;2.5 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is frequently difficult to achieve an adequate dietary intake without supplementation, which can be administered either orally or enterally. In children on HD, guidelines from both the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/29\">",
"     29",
"    </a>",
"    ] and United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/30\">",
"     30",
"    </a>",
"    ] recommend a normal carbohydrate intake and an increase in the recommended protein intake for an age matched population. The increase in protein intake is recommended to be 0.1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day (but may need to be more in very small children) to allow for losses of amino acids into the dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are four studies of intradialytic parenteral nutrition during HD in children, but patient numbers are small, so it is difficult to draw conclusions about its effectiveness as a nutrition supplement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241185873\">",
"    <span class=\"h3\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, growth has been poor in children undergoing HD. As an example, data from the NAPRTCS demonstrated that height SDS decreased from -1.64 to -1.71 after one year of dialysis, and fell further to -1.84 at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it appears that an early and more intensive approach to nutrition is able to maintain or even improve height SDS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. This was illustrated in a study of 101 children presenting with CKD stage 4 or 5 before the age of two years of whom 89 percent were enterally fed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/34\">",
"     34",
"    </a>",
"    ]. In this cohort, the mean height SDS improved from -2.18 at age six months to -0.87 at five years. Those without a comorbid condition achieved a mean normal adult height without the administration of recombinant growth hormone (rhGH) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=see_link&amp;anchor=H359700278#H359700278\">",
"     \"Prevention and management of growth failure in children with chronic kidney disease\", section on 'Nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RhGH may, however, be recommended in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/37\">",
"     37",
"    </a>",
"    ]. This approach of early intensive nutrition and the selective use of rhGH has led to an improvement in growth over the years, such that children who started dialysis at &lt;18 months of age between 1983 and 1995 had a height SDS of -3.0 compared with -1.4 of those patients who initiated HD between 1996 and 2008. This improvement appears to be due to better control of renal bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/36\">",
"     36",
"    </a>",
"    ] and the increased use of enteral feeding (including both tube and gastrostomy feeding) and rhGH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760129\">",
"    <span class=\"h2\">",
"     Neuropsychological outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with CKD have a higher incidence of syndromes and other independent developmental abnormalities compared with the general pediatric population, which impact neurodevelopmental and psychosocial outcome. However, even with controlling for these co-morbidities, pediatric patients with CKD have significant neuropsychological impairment.",
"   </p>",
"   <p>",
"    In one study of children who initiated HD before 18 months, 42 percent had significant neuropsychological impairment of which 25 percent required special education and 13 percent were severely handicapped requiring residential care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/31\">",
"     31",
"    </a>",
"    ]. The remaining 58 percent attended regular school. Other studies have reported more encouraging results; children with CKD 5 had mild deficits of IQ and fine motor coordination in comparison with their siblings, but there were no differences in measures of academic achievement, memory, behavior, or self-esteem [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/39\">",
"     39",
"    </a>",
"    ]. It appears that children who have had a longer period of time on dialysis are more likely to have cognitive and learning impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760137\">",
"    <span class=\"h2\">",
"     Mineral and bone disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal mineral metabolism, and altered bone structure and composition are almost universal in children on dialysis and result in bone and joint pain, fractures (the most common disability in young adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/41\">",
"     41",
"    </a>",
"    ], and vascular calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of bone metabolism in children with CKD differs from adults because of the increased requirement for calcium in children, the higher normal ranges for calcium and phosphate in early childhood, and the ability to prevent hyperparathyroidism as children usually present earlier in the evolution of CKD. The management of these issues in children with CKD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"     \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760145\">",
"    <span class=\"h2\">",
"     Cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike adults, the traditional risk factors for cardiovascular disease (CVD), diabetes, obesity, dyslipidemia, and smoking, are uncommon in children. Hypertension is the most important CVD risk factor, particularly in children undergoing HD. In one case series of 624 children on HD, hypertension was present in 79 percent, with 62 percent receiving antihypertensive medication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/43\">",
"     43",
"    </a>",
"    ]. Markers of CVD including abnormal endothelial function and pulse wave velocity, increased carotid-intima-media thickness, and vascular calcification have been found in children on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/42,44-46\">",
"     42,44-46",
"    </a>",
"    ]. Left ventricular (LV) remodelling and LV hypertrophy have also been reported in 30 to 80 percent of pediatric dialysis patients with a higher incidence in HD than PD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/47\">",
"     47",
"    </a>",
"    ]. As discussed above, hypertension is primarily due to excess fluid and can best be prevented by increasing dialysis time. (See",
"    <a class=\"local\" href=\"#H6760083\">",
"     'Length of dialysis and frequency of sessions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6760099\">",
"     'Fluid removal'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Atherosclerotic changes in childhood'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Risk for cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children on HD, like adults, suffer from myocardial stunning defined as abnormal regional left ventricular wall motion, which may, if repeated, lead to permanent myocardial damage. Myocardial stunning is associated with intradialytic hypotension and may be more common in pediatric patients because of the predominantly liquid diet in infants, increased noncompliance with fluid restriction, and the drive for attainment of optimum weight in the children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link&amp;anchor=H8#H8\">",
"     \"Myocardial dysfunction in end-stage renal disease\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia is also a frequent finding in children undergoing dialysis and is associated with an increased risk for mortality, left ventricular hypertrophy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased exercise capacity. In the United Kingdom, 47 percent of the pediatric dialysis population had a hemoglobin",
"    <span class=\"nowrap\">",
"     &lt;11gm/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/49\">",
"     49",
"    </a>",
"    ]. Anemia as a complication of CKD in children and its management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760153\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760161\">",
"    <span class=\"h2\">",
"     Mortality rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality risk for children on dialysis is &gt;30 times higher than age and gender matched normal children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In the United States, five year survival of 2867 patients starting dialysis at ages &lt;1, 1 to 5, and &gt;5 years was 60, 80, and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/6\">",
"     6",
"    </a>",
"    ]. Data from the ANZDATA registry of children starting RRT from 1963 and 2002 demonstrated a 10 and 20 year survival of 79 and 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality is considerably higher in children on dialysis than post transplant, as noted by data from ANZDATA reporting a fourfold higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/50\">",
"     50",
"    </a>",
"    ], and the United Network for Organ Sharing a tenfold higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/52\">",
"     52",
"    </a>",
"    ] of death in children on dialysis compared with those who were transplanted. In the Netherlands, the ERA-ERDTA registry reported a five year overall unadjusted survival data for young adults from age 18 who began RRT during childhood as 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the average life expectancy of patients with a functioning graft was considerably greater than those on dialysis (63 versus 38 years of age).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760168\">",
"    <span class=\"h3\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD) is the cause of death in up to 50 percent of children with CKD and is more common after 10 years of RRT. Other causes include comorbid conditions (eg, congenital heart disease and severe neurologic impairment), treatment withdrawal (with or without comorbidity), failure to obtain or maintain dialysis access, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/35,50,51\">",
"     35,50,51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6760197\">",
"     'Co-morbidity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link&amp;anchor=H5#H5\">",
"     \"Diseases associated with atherosclerosis in childhood\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of death from CVD is 1000-fold higher in young adults on dialysis than in the age matched normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/54\">",
"     54",
"    </a>",
"    ]. CVD is the cause of 22.5 percent of deaths in the USRDS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/6\">",
"     6",
"    </a>",
"    ], 45 percent in the ANZDATA registry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/7\">",
"     7",
"    </a>",
"    ], and 41 percent in the Dutch registry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/51\">",
"     51",
"    </a>",
"    ]. In the largest study of 1454 pediatric patients, who were dialyzed from 1991 to 1996, 31 percent developed a cardiac-related event, including arrhythmias (19.6 percent), valvular disease (11.7 percent), cardiomyopathy (9.6 percent), and death from cardiac arrest (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/55\">",
"     55",
"    </a>",
"    ]. Unlike adults with CKD in whom coronary artery disease is the leading cause of death, cardiac arrest is the most common etiology in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760182\">",
"    <span class=\"h3\">",
"     Factors influencing survival",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760190\">",
"    <span class=\"h4\">",
"     Era of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in survival rates based on era of treatment are conflicting. This is not surprising because it is challenging to compare survival rates over time with changes in the population treated, as children with potentially poorer outcome have been increasingly accepted for RRT. These include young infants with CKD and those with severe co-morbidities. Acceptance rates for such children vary, affecting not only outcome data over time, but also results from different parts of the world, because centers and countries will have different acceptance criteria.",
"   </p>",
"   <p>",
"    Despite the above issues, several studies have demonstrated improved survival rates over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the ANZDATA registry report an improvement in mortality, from 11 per 100 patient years between 1963 and 1972 to 1.8 per 100 patient years in those starting dialysis after 1993 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Dutch patients, the 5 and 10 year survival rates improved from 81 and 79 percent to 89 and 85 percent for patients treated between 1972 and 1981 compared with those treated from 1982 to 1991 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/51\">",
"       51",
"      </a>",
"      ]. However, this cohort included patients with a functioning graft.",
"     </li>",
"     <li>",
"      Data from the NAPRTCS registry showed that infants who started dialysis between 1999 and 2005 compared with 1992 and 1998 had an improved three year survival [",
"      <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the 2009 USRDS report showed no significant change in the five year survival of children on dialysis over the last decade, with rates of 69 percent in 1990 and 71 percent in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/6\">",
"     6",
"    </a>",
"    ]. In this report, children aged 10 to 14 years on hemodialysis (HD) actually had a deceased survival rate. In addition, a single center reported similar mortality for infants starting dialysis aged &lt;18 months during two different eras from 1983 to 1995 and 1996 to 2008, with an overall mortality of 54 percent over 25 years observation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760197\">",
"    <span class=\"h4\">",
"     Co-morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidities are common, occurring in about 30 percent of infants and young children who receive HD. This subgroup of patients is thought to cause about 75 percent of deaths, and comorbidity increases the risk of death 7.5 fold [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/32\">",
"     32",
"    </a>",
"    ]. The effect of comorbidity on survival extends into adulthood as childhood survivors of dialysis with comorbidity have a significantly higher risk of death compared with those with only primary renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760204\">",
"    <span class=\"h4\">",
"     Age at start of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All reports show significantly higher mortality in young children starting dialysis, although this group also has the highest incidence of comorbid conditions. Data from the ANZDATA registry showed a lower five year survival for patients under one year of age compared with the overall cohort (73 versus 86 percent), and there was a fourfold increased risk of death for infants compared with children ages 15 to 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/50\">",
"     50",
"    </a>",
"    ]. NAPRTCS registry also report lower survival rates for children who began HD before one year of age with survival rates of 82, 73, and 65 percent at one, two, and three years after initiation of HD, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/56\">",
"     56",
"    </a>",
"    ]. Most deaths occur in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/32,38,57\">",
"     32,38,57",
"    </a>",
"    ]. For infants after one year of age and without comorbidity, there are no differences in rates of survival than other age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, mortality is lower in children than adults undergoing dialysis. The adjusted annual mortality rate for pediatric dialysis patients (age 0 to 19 years) is 52.9 compared with 90, 156.2, and 253.1 per 1000 patient years at risk for adult patients age 20 to 44 years, 45 to 64 year, and 65 to 74 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760211\">",
"    <span class=\"h4\">",
"     Modality of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparisons of survival between HD and PD are challenging primarily because younger children, who have the highest mortality, are more often managed by PD. However, the Italian registry found no difference in survival between PD and HD in children between 5 and 15 years, although those aged &lt;5 years, who were almost exclusively managed on PD, had a poorer five year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/58\">",
"     58",
"    </a>",
"    ]. USRDS data showed no difference in five year survival at any age, or in the incidence of CVD, which accounted for 57 percent of deaths in children on HD and 43 percent of those on PD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760219\">",
"    <span class=\"h4\">",
"     Primary renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with oligoanuria are more difficult to manage and do particularly poorly, with an odds ratio for death 41 times greater than that of infants without oligoanuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/38\">",
"     38",
"    </a>",
"    ]. This is partly due to the associated complication of pulmonary hypoplasia, which is caused by oligohydramnios due to fetal oligoanuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. As an example, autosomal recessive polycystic kidney disease, which is often associated with pulmonary hypoplasia, has an increased mortality odds ratio of 20 compared with other genetic or congenital causes of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/38\">",
"     38",
"    </a>",
"    ]. Infants with congenital nephrotic syndrome also do less well [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Amniotic fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H496449798\">",
"    <span class=\"h2\">",
"     Long-term quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of quality of life indices have given some surprising results. Children on dialysis have lower health-related quality of life scores (HRQOL) than healthy controls but higher scores than expected compared with those of transplanted children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, parents of transplanted children report significantly better HRQOL scores compared with parents of children on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/62\">",
"     62",
"    </a>",
"    ]. The Dutch registry reported that the overall subjective health perception of children with CKD was good, despite the unavoidable physical problems; however, young adult survivors of prolonged dialysis during childhood were twice as likely to be unemployed than an age matched population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/1/9242/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760227\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the principles of hemodialysis (HD) are similar for adults and children, there are fundamental differences in the technical aspects of the procedure and complications. It is crucial that these unique aspects are addressed in order to effectively and safely perform pediatric HD and reduce potential complications, thereby improving life expectancy and quality of life for these patients who face a lifetime of renal replacement therapy. Optimal care is provided by a multidisciplinary team that manages dialysis treatment and nutrition, ensures effective vascular access, and provides psychosocial support. (See",
"    <a class=\"local\" href=\"#H118551084\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good vascular access is essential for successful HD. Because of technical difficulties in creating native arteriovenous (AV) fistulas, especially in infants and small children, the desire to avoid needling the access, and the anticipation of a short course of dialysis, HD is initiated through a percutaneous catheter in the majority of children. However, arteriovenous fistulas have been shown to be more effective for HD and have fewer side effects. As a result, we suggest placement of an AV fistula for initiation of HD in children who are large enough that this is technically feasible, are not likely to receive a transplant within six months, and are tolerant of access needling (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In these settings, a percutaneous CVC is used to initiate HD. The size and length of the catheter is determined by the size of the child and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      vessels (",
"      <a class=\"graphic graphic_table graphicRef57580 \" href=\"UTD.htm?35/36/36427\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6760051\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The HD equipment must be modified for pediatric patients, particularly infants and small children, as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Selection of the HD tubing and dialyzer to ensure that the volume of the extracorporeal circuit does not exceed the upper limit of safety, which is 8 to 10 percent of their total blood volume (",
"      <a class=\"graphic graphic_table graphicRef77610 \" href=\"UTD.htm?18/34/18987\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H241185639\">",
"       'Extracorporeal circuit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The size of the dialyzer is dependent on the size of the child and should match",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      surface area. (See",
"      <a class=\"local\" href=\"#H241185624\">",
"       'Dialyzer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dialysis machine used in children should have the capabilities to remove small amounts of fluid, directly measure the volume removed, and use low blood flow rates, and lines of varying blood volumes. (See",
"      <a class=\"local\" href=\"#H6760075\">",
"       'HD machine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dialysis prescription for each patient includes the chosen dialyzer (including size), blood flow rates, length and frequency of dialysis sessions, and the amount of fluid to be removed each session based on the estimation of the optimum weight. (See",
"      <a class=\"local\" href=\"#H167575180\">",
"       'Dialysis prescription'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that evaluation of the adequacy of dialysis using measures of dialyzer clearance of urea",
"      <span class=\"nowrap\">",
"       (Kt/V),",
"      </span>",
"      protein catabolic rate, and growth be performed once a month in children who receive chronic HD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6760107\">",
"       'Measurements of adequacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications seen in children who receive chronic HD include malnutrition, poor growth, and increased risk of neurodevelopmental and psychosocial impairment, mineral and bone disorders, and cardiovascular disease. The use of HDF and more frequent dialysis is likely to be of benefit to these complications. (See",
"      <a class=\"local\" href=\"#H6760115\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality is 30 times higher in children on dialysis compared with gender matched normal children. The major cause of death is due to cardiovascular disease. Risk factors that increase mortality include the presence of comorbid conditions (eg, severe neurologic impairment and congenital heart disease), initiation of dialysis before one year of age, and primary renal diseases associated with oligoanuria, pulmonary hypoplasia, and congenital nephrotic syndrome. (See",
"      <a class=\"local\" href=\"#H6760161\">",
"       'Mortality rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, long-term quality of life is lower in children on dialysis compared with normal healthy controls and children who receive a renal transplant. (See",
"      <a class=\"local\" href=\"#H496449798\">",
"       'Long-term quality of life'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/1\">",
"      Briones L, Diaz Moreno A, Sierre S, et al. Permanent vascular access survival in children on long-term chronic hemodialysis. Pediatr Nephrol 2010; 25:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/2\">",
"      Eisenstein I, Tarabeih M, Magen D, et al. Low infection rates and prolonged survival times of hemodialysis catheters in infants and children. Clin J Am Soc Nephrol 2011; 6:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/3\">",
"      Ma A, Shroff R, Hothi D, et al. A comparison of arteriovenous fistulas and central venous lines for long-term chronic haemodialysis. Pediatr Nephrol 2013; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/4\">",
"      Manook M, Calder F. Practical aspects of arteriovenous fistula formation in the pediatric population. Pediatr Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2008 Annual Report: Renal transplantation, dialysis, chronic renal insufficiency. Available at: https://web.emmes.com/study/ped/annlrept/annlrept2008.pdf (Accessed on March 11, 2011).",
"    </li>",
"    <li>",
"     US Renal Data System. The Concise 2009 Annual Data Report: Atlas of Chronic kidney disease and End-stage Renal Disease in the US. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.",
"    </li>",
"    <li>",
"     McTaggart S, Kennedy S, McDonald S, et al. Paediatric Report. ANZDATA Registry 2009 Report. Available at: file://www.anzdata.org.au/anzdata/AnzdataReport/32ndReport/Ch11.pdf. (Accessed on February 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/8\">",
"      Hayes WN, Watson AR, Callaghan N, et al. Vascular access: choice and complications in European paediatric haemodialysis units. Pediatr Nephrol 2012; 27:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/9\">",
"      Chand DH, Brier M, Strife CF. Comparison of vascular access type in pediatric hemodialysis patients with respect to urea clearance, anemia management, and serum albumin concentration. Am J Kidney Dis 2005; 45:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/10\">",
"      Fischbach M, Edefonti A, Schr&ouml;der C, et al. Hemodialysis in children: general practical guidelines. Pediatr Nephrol 2005; 20:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/11\">",
"      Dorsett-Martin WA. Review of microsurgery and arteriovenous fistulae for hemodialysis. Microsurgery 2006; 26:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/12\">",
"      Zaritsky JJ, Salusky IB, Gales B, et al. Vascular access complications in long-term pediatric hemodialysis patients. Pediatr Nephrol 2008; 23:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/13\">",
"      M&uuml;ller D, Zimmering M, Chan CT, et al. Intensified hemodialysis regimens: neglected treatment options for children and adolescents. Pediatr Nephrol 2008; 23:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/14\">",
"      Goldstein SL, Silverstein DM, Leung JC, et al. Frequent hemodialysis with NxStage system in pediatric patients receiving maintenance hemodialysis. Pediatr Nephrol 2008; 23:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/15\">",
"      Geary DF, Piva E, Tyrrell J, et al. Home nocturnal hemodialysis in children. J Pediatr 2005; 147:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/16\">",
"      Fischbach M, Terzic J, Menouer S, et al. Intensified and daily hemodialysis in children might improve statural growth. Pediatr Nephrol 2006; 21:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/17\">",
"      Hothi DK, Harvey E, Piva E, et al. Calcium and phosphate balance in adolescents on home nocturnal haemodialysis. Pediatr Nephrol 2006; 21:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/18\">",
"      Fischbach M, Terzic J, Menouer S, et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant 2010; 25:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/19\">",
"      Hoppe A, von Puttkamer C, Linke U, et al. A hospital-based intermittent nocturnal hemodialysis program for children and adolescents. J Pediatr 2011; 158:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/20\">",
"      Hothi DK, Stronach L, Harvey E. Home haemodialysis. Pediatr Nephrol 2013; 28:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/21\">",
"      Shroff R. Can dialysis modality influence cardiovascular outcome? Pediatr Nephrol 2012; 27:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/22\">",
"      Davenport A. Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments. Pediatr Nephrol 2012; 27:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/23\">",
"      Gorman G, Furth S, Hwang W, et al. Clinical outcomes and dialysis adequacy in adolescent hemodialysis patients. Am J Kidney Dis 2006; 47:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/24\">",
"      Juarez-Congelosi M, Orellana P, Goldstein SL. Normalized protein catabolic rate versus serum albumin as a nutrition status marker in pediatric patients receiving hemodialysis. J Ren Nutr 2007; 17:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/25\">",
"      Wong CS, Hingorani S, Gillen DL, et al. Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease. Kidney Int 2002; 61:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/26\">",
"      Amaral S, Hwang W, Fivush B, et al. Serum albumin level and risk for mortality and hospitalization in adolescents on hemodialysis. Clin J Am Soc Nephrol 2008; 3:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/27\">",
"      Wong CS, Gipson DS, Gillen DL, et al. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis 2000; 36:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/28\">",
"      Furth SL, Stablein D, Fine RN, et al. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 2002; 109:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/29\">",
"      Rees L, Shaw V. Nutrition in children with CRF and on dialysis. Pediatr Nephrol 2007; 22:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/30\">",
"      Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Rees L. Management issues in children with renal disease; growth, nutrition and pubertal development. In: Evidence-Based Nephrology, Molony DA, Craig JC (Eds), Wiley-Blackwell, Malden, MA 2009. p.654.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/32\">",
"      Shroff R, Rees L, Trompeter R, et al. Long-term outcome of chronic dialysis in children. Pediatr Nephrol 2006; 21:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/33\">",
"      Ledermann SE, Scanes ME, Fernando ON, et al. Long-term outcome of peritoneal dialysis in infants. J Pediatr 2000; 136:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/34\">",
"      Kari JA, Gonzalez C, Ledermann SE, et al. Outcome and growth of infants with severe chronic renal failure. Kidney Int 2000; 57:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/35\">",
"      Mekahli D, Shaw V, Ledermann SE, Rees L. Long-term outcome of infants with severe chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/36\">",
"      Cansick J, Waller S, Ridout D, Rees L. Growth and PTH in prepubertal children on long-term dialysis. Pediatr Nephrol 2007; 22:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/37\">",
"      Seikaly MG, Salhab N, Warady BA, Stablein D. Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS. Pediatr Nephrol 2007; 22:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/38\">",
"      Hijazi R, Abitbol CL, Chandar J, et al. Twenty-five years of infant dialysis: a single center experience. J Pediatr 2009; 155:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/39\">",
"      Bawden HN, Acott P, Carter J, et al. Neuropsychological functioning in end-stage renal disease. Arch Dis Child 2004; 89:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/40\">",
"      Groothoff JW, Grootenhuis M, Dommerholt A, et al. Impaired cognition and schooling in adults with end stage renal disease since childhood. Arch Dis Child 2002; 87:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/41\">",
"      Groothoff JW. Long-term outcomes of children with end-stage renal disease. Pediatr Nephrol 2005; 20:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/42\">",
"      Shroff RC, Donald AE, Hiorns MP, et al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18:2996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/43\">",
"      Chavers BM, Solid CA, Daniels FX, et al. Hypertension in pediatric long-term hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/44\">",
"      Shroff R, Egerton M, Bridel M, et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/45\">",
"      Litwin M, W&uuml;hl E, Jourdan C, et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 2005; 16:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/46\">",
"      Covic A, Mardare N, Gusbeth-Tatomir P, et al. Increased arterial stiffness in children on haemodialysis. Nephrol Dial Transplant 2006; 21:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/47\">",
"      Mitsnefes MM. Cardiovascular morbidity and mortality in children with chronic kidney disease in North America: lessons from the USRDS and NAPRTCS databases. Perit Dial Int 2005; 25 Suppl 3:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/48\">",
"      Hothi DK, Rees L, Marek J, et al. Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 2009; 4:790.",
"     </a>",
"    </li>",
"    <li>",
"     Verrier-Jones K RC, Evans J, Webb N, et al. Aspects of anaemia management in children with established renal failure: Royal College of Physicians and the Renal Association; 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/50\">",
"      McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/51\">",
"      Groothoff JW, Gruppen MP, Offringa M, et al. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 2002; 61:621.",
"     </a>",
"    </li>",
"    <li>",
"     UNOS. 2002 Annual report of the US scientific registry of transplant recipients and the organ procurement and transplantation network; transplant data 1992-2001: United Network for Organ Sharing, Rockville, MD; 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/53\">",
"      Kramer A, Stel VS, Tizard J, et al. Characteristics and survival of young adults who started renal replacement therapy during childhood. Nephrol Dial Transplant 2009; 24:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/54\">",
"      Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/55\">",
"      Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002; 141:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/56\">",
"      Carey WA, Talley LI, Sehring SA, et al. Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis. Pediatrics 2007; 119:e468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/57\">",
"      Wood EG, Hand M, Briscoe DM, et al. Risk factors for mortality in infants and young children on dialysis. Am J Kidney Dis 2001; 37:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/58\">",
"      Verrina E, Edefonti A, Gianoglio B, et al. A multicenter experience on patient and technique survival in children on chronic dialysis. Pediatr Nephrol 2004; 19:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/59\">",
"      Shroff R, Wright E, Ledermann S, et al. Chronic hemodialysis in infants and children under 2 years of age. Pediatr Nephrol 2003; 18:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/60\">",
"      Goldstein SL, Graham N, Burwinkle T, et al. Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 2006; 21:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/61\">",
"      McKenna AM, Keating LE, Vigneux A, et al. Quality of life in children with chronic kidney disease-patient and caregiver assessments. Nephrol Dial Transplant 2006; 21:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/1/9242/abstract/62\">",
"      Goldstein SL, Rosburg NM, Warady BA, et al. Pediatric end stage renal disease health-related quality of life differs by modality: a PedsQL ESRD analysis. Pediatr Nephrol 2009; 24:1553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14562 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9242=[""].join("\n");
var outline_f9_1_9242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6760227\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118550430\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118551084\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60775273\">",
"      Multidisciplinary team",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6760051\">",
"      VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H118551405\">",
"      Tunneled catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349365238\">",
"      AV fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H167575172\">",
"      HD EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H241185639\">",
"      Extracorporeal circuit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760067\">",
"      Dialyzer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760075\">",
"      HD machine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H167575180\">",
"      DIALYSIS PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H241185624\">",
"      Dialyzer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6761650\">",
"      Blood flows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760083\">",
"      Length of dialysis and frequency of sessions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760099\">",
"      Fluid removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H167575773\">",
"      - Estimation of optimum weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4695269\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6760107\">",
"      MEASUREMENTS OF ADEQUACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6760115\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760122\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H241185873\">",
"      - Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760129\">",
"      Neuropsychological outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760137\">",
"      Mineral and bone disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760145\">",
"      Cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6760153\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760161\">",
"      Mortality rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6760168\">",
"      - Causes of death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6760182\">",
"      - Factors influencing survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6760190\">",
"      Era of dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6760197\">",
"      Co-morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6760204\">",
"      Age at start of dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6760211\">",
"      Modality of dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6760219\">",
"      Primary renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H496449798\">",
"      Long-term quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6760227\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14562|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/43/21183\" title=\"picture 1\">",
"      Pediatric hemodialysis split catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/36/36427\" title=\"table 1\">",
"      Catheter size for pediatric hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/34/18987\" title=\"table 2\">",
"      Volumes of hemodialysis lines based on patient weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30330?source=related_link\">",
"      Alternative renal replacement therapies in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=related_link\">",
"      Overview of the hemodialysis apparatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=related_link\">",
"      Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17240?source=related_link\">",
"      Prevention and management of growth failure in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_1_9243="Early postnatal weight";
var content_f9_1_9243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early postnatal growth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Weight loss (percent)",
"       </td>",
"       <td>",
"        5 to &lt;7",
"       </td>",
"       <td>",
"        &gt;7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Duration of weight loss (day)",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Time to regain birthweight (week)",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        &gt;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"5\">",
"        Intervention",
"       </td>",
"       <td rowspan=\"5\">",
"        Routine management&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Evaluate lactation management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rule out primary lactation failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rule out infant oral-motor abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor closely, including daily weights",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider supplementation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9243=[""].join("\n");
var outline_f9_1_9243=null;
var title_f9_1_9244="Etiology of hemoptysis";
var content_f9_1_9244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hemoptysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Airway disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute or chronic bronchitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchovascular fistulae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dieulafoy's disease (superficial, subepithelial bronchial artery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary parenchymal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic defect in connective tissue (Ehlers-Danlos vascular type)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection (especially tuberculosis, pneumonia, mycetoma, or lung abscess)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory or immune disorders (eg, granulomatosis with polyangiitis [Wegener's], Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, lupus pneumonitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary vascular disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrial hypertension (eg, mitral valve disease, poor left ventricular performance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary arteriovenous malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bevacizumab treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catamenial hemoptysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrogen dioxide toxicity (eg, silo fillers, indoor ice arenas with faulty propane powered equipment and poor ventilation)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9244=[""].join("\n");
var outline_f9_1_9244=null;
var title_f9_1_9245="Umbilical Vein and Artery pH";
var content_f9_1_9245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Umbilical vein and artery pH",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        GA",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Umbilical vein pH",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Umbilical artery pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th percentile",
"       </td>",
"       <td class=\"subtitle2\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        7.385",
"       </td>",
"       <td>",
"        7.423",
"       </td>",
"       <td>",
"        7.461",
"       </td>",
"       <td>",
"        7.360",
"       </td>",
"       <td>",
"        7.398",
"       </td>",
"       <td>",
"        7.435",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        7.382",
"       </td>",
"       <td>",
"        7.420",
"       </td>",
"       <td>",
"        7.458",
"       </td>",
"       <td>",
"        7.357",
"       </td>",
"       <td>",
"        7.394",
"       </td>",
"       <td>",
"        7.431",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        7.379",
"       </td>",
"       <td>",
"        7.417",
"       </td>",
"       <td>",
"        7.454",
"       </td>",
"       <td>",
"        7.353",
"       </td>",
"       <td>",
"        7.390",
"       </td>",
"       <td>",
"        7.427",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        7.376",
"       </td>",
"       <td>",
"        7.414",
"       </td>",
"       <td>",
"        7.451",
"       </td>",
"       <td>",
"        7.350",
"       </td>",
"       <td>",
"        7.386",
"       </td>",
"       <td>",
"        7.423",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        7.373",
"       </td>",
"       <td>",
"        7.410",
"       </td>",
"       <td>",
"        7.448",
"       </td>",
"       <td>",
"        7.346",
"       </td>",
"       <td>",
"        7.383",
"       </td>",
"       <td>",
"        7.419",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        7.370",
"       </td>",
"       <td>",
"        7.407",
"       </td>",
"       <td>",
"        7.445",
"       </td>",
"       <td>",
"        7.342",
"       </td>",
"       <td>",
"        7.379",
"       </td>",
"       <td>",
"        7.416",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        7.366",
"       </td>",
"       <td>",
"        7.404",
"       </td>",
"       <td>",
"        7.442",
"       </td>",
"       <td>",
"        7.338",
"       </td>",
"       <td>",
"        7.375",
"       </td>",
"       <td>",
"        7.412",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        7.363",
"       </td>",
"       <td>",
"        7.401",
"       </td>",
"       <td>",
"        7.439",
"       </td>",
"       <td>",
"        7.334",
"       </td>",
"       <td>",
"        7.371",
"       </td>",
"       <td>",
"        7.409",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        7.360",
"       </td>",
"       <td>",
"        7.398",
"       </td>",
"       <td>",
"        7.436",
"       </td>",
"       <td>",
"        7.330",
"       </td>",
"       <td>",
"        7.368",
"       </td>",
"       <td>",
"        7.406",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        7.357",
"       </td>",
"       <td>",
"        7.395",
"       </td>",
"       <td>",
"        7.433",
"       </td>",
"       <td>",
"        7.325",
"       </td>",
"       <td>",
"        7.364",
"       </td>",
"       <td>",
"        7.403",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        7.353",
"       </td>",
"       <td>",
"        7.392",
"       </td>",
"       <td>",
"        7.430",
"       </td>",
"       <td>",
"        7.321",
"       </td>",
"       <td>",
"        7.360",
"       </td>",
"       <td>",
"        7.399",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        7.350",
"       </td>",
"       <td>",
"        7.388",
"       </td>",
"       <td>",
"        7.427",
"       </td>",
"       <td>",
"        7.317",
"       </td>",
"       <td>",
"        7.357",
"       </td>",
"       <td>",
"        7.396",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    pH values were determined by cordocentesis in fetuses whose mothers were not in labor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9245=[""].join("\n");
var outline_f9_1_9245=null;
var title_f9_1_9246="Cutaneobiliary fistula";
var content_f9_1_9246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneobiliary fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneobiliary fistula as seen through the cholangioscope. The guidewire can be seen in the upper portion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jurgen F Riemann, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9246=[""].join("\n");
var outline_f9_1_9246=null;
var title_f9_1_9247="AP view transverse patella fracture";
var content_f9_1_9247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AP view of transverse patella fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note how the fracture line (arrow) is relatively narrow and irregular compared with the bipartite patella. Also note that the location of the fracture line does not correspond with any of the common ossification centers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_1_9247=[""].join("\n");
var outline_f9_1_9247=null;
